Document:

EX-10.8 Agreement between Teva & Protalix

 

Exhibit 10.8

Portions of this exhibit have been omitted pursuant to a request for confidential treatment.
The omitted portions, marked by [***], have been separately filed with the Securities and Exchange
Commission.

AGREEMENT

made and signed on this 14 day of September, 2006

Between

Teva Pharmaceutical Industries Ltd.

a limited liability company incorporated under the laws of Israel, of 5 Basel Street, Petach Tiqva

49131, Israel

(“Teva”)

and

Protalix Biopharmaceuticals Ltd.

a limited liability company incorporated under the laws of Israel, of 2 Snunit St., Science Park

P.O. Box 455, Carmiel 20100 , Israel

(“Protalix”)

Teva and Protalix may be individually referred to as a “Party” and collectively as the “Parties”

WHEREAS, the Parties wish to carry out a Feasibility Program (as defined herein) to evaluate their
potential collaboration in the development and manufacturing of two Proteins (as such term is
defined below) on the basis of Protalix’s proprietary plant culture process, as more fully
described herein;

WHEREAS, the Parties agree, that following the completion of such Feasibility Program, Teva shall
have the option, but not the obligation, to enter into further collaboration with Protalix
regarding the development of Licensed Products (as defined herein), all as more fully set forth
herein and in accordance with the terms and conditions of this Agreement;

WHEREAS, the Parties agree that in the event that Teva shall exercise the aforementioned option to
enter into the collaboration regarding the development of Licensed Products, Protalix shall grant
to Teva and Teva shall acquire from Protalix, the License (as defined herein), all subject to and
in accordance with the terms and conditions of this Agreement; and

WHEREAS, Protalix agrees to grant Teva a right of first look at Protalix’s proprietary product(s)
for the treatment of Gauchers Disease, to enable Teva to evaluate its interest in negotiating and
obtaining the GCD License (as such term is defined herein), all subject to and in accordance with
the terms and conditions set out hereinbelow.

NOW, THEREFORE, the Parties, agree as follows:

	1.	 	Preamble and Definitions

	 	1.1.	 	The Preamble and Annexes hereto form an integral part of this Agreement.

 

 - 1 - 

 

	 	1.2.	 	In this Agreement the terms below shall bear the meanings assigned to them
below and other capitalized terms shall bear the meaning assigned to them in their
parenthetical definition, unless specifically stated otherwise:

	 	1.2.1.	 	“Additional Patents” - shall mean the patents and patent
applications listed in Annex 1.2.1, which constitute all of the patents and
patent applications that are proprietary to Protalix and existing on the
Effective Date, other than the Platform Patents and patent application number
[***] entitled [***], and any patent that may be issued thereon.
	 
	 	1.2.2.	 	“Affiliate” shall mean, with respect to any Party, any person,
organization or entity directly or indirectly controlling, controlled by or
under common control with, such Party. For purposes of this definition only,
“control” of another person, organization or entity shall mean the ability,
directly or indirectly, to direct the activities of the relevant entity, and
shall include, without limitation (i) ownership or direct control of fifty
percent (50%) or more of the outstanding voting stock or other ownership
interest of the other organization or entity, or (ii) direct or indirect
possession, of the power to elect or appoint fifty percent (50%) or more of
the members of the governing body of the organization or other entity.
	 
	 	1.2.3.	 	“Annual Protalix Payment” shall bear the meaning assigned to such
term in Section 10.5 below.
	 
	 	1.2.4.	 	“API” shall mean the bulk Proteins’ active pharmaceutical
ingredient.
	 
	 	1.2.5.	 	“API COGS” shall bear the meaning assigned to such term in Section
10.4 below.
	 
	 	1.2.6.	 	“Backup Manufacturing File” shall bear the meaning assigned to
such term in Section 10.7 below.
	 
	 	1.2.7.	 	“Breakthrough Technology” shall bear the meaning assigned to such
term in Section 13.2 below.
	 
	 	1.2.8.	 	“Budget” shall bear the meaning assigned to such term in Section
4.14 below.
	 
	 	1.2.9.	 	“Combination Product” shall mean a product which comprises (a) a
Licensed Product and (b) at least one other active ingredient, which, if
administered independently of the Licensed Product, would have a clinical
effect.
	 
	 	1.2.10.	 	“Change of Control” shall bear the meaning assigned to such term
in Section 11.5 below.
	 
	 	1.2.11.	 	“Commercial GCD Services” shall bear the meaning assigned to such
term in Section 14A.6 below.
	 
	 	1.2.12.	 	“Development Plan” shall bear the meaning assigned to such term
in Section 4.4 below.
	 
	 	1.2.13.	 	“Effective Date” shall bear the meaning assigned to such term in
Section 15.1 below.
	 
	 	1.2.14.	 	“EU” shall mean the member countries of the European Union, from
time to time.
	 
	 	1.2.15.	 	“EU Market” shall mean all of Spain, the UK, Italy, Germany and
France.

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 2 - 

 

	 	1.2.16.	 	“Evaluation Period” shall bear the meaning assigned to such term
in Section 14.2 below.
	 
	 	1.2.17.	 	“External Development Expenses” shall bear the meaning assigned
to such term in Section 4.14.2 below.
	 
	 	1.2.18.	 	“External Manufacturing Expenses” shall bear the meaning assigned
to such term in Section 10.4 below.
	 
	 	1.2.19.	 	“Exclusive Manufacturing Term” shall bear the meaning assigned to
such term in Section 10.1 below.
	 
	 	1.2.20.	 	“Escrow Agent” shall bear the meaning assigned to such term in
Section 10.7(A) below.
	 
	 	1.2.21.	 	“Feasibility Program(s)” shall bear the meaning assigned to such
term in Section 3.1.1 below.
	 
	 	1.2.22.	 	“Final Feasibility Report” shall bear the meaning assigned to
such term in Section 3.1.7 below.
	 
	 	1.2.23.	 	“First Commercial Sale” shall mean, with respect to any Licensed
Product the first commercial sale to a third party, in exchange for cash or
some equivalent to which value can be assigned, after the obtaining of all
necessary regulatory and other approvals required in order to commercially
sell and market the Licensed Product in the country in which the sale is made,
other than the sale of the Licensed Product for experimental, testing,
compassionate or promotional purposes.
	 
	 	1.2.24.	 	“Further Sublicense” and “Further Sublicensee” shall bear the
meaning assigned to such terms in Section 6.3 below.
	 
	 	1.2.25.	 	“GCD License” shall bear the meaning assigned to such term in
Section 14.1 below.
	 
	 	1.2.26.	 	“GCD Product” shall bear the meaning assigned to such term in
Section 14.1 below.
	 
	 	1.2.27.	 	“GCD Services” shall bear the meaning assigned to such term in
Section 14A.1 below.
	 
	 	1.2.28.	 	“Innovator” shall mean the first to market with a specific
proprietary Product.
	 
	 	1.2.29.	 	“Internal Expenses” shall bear the meaning assigned to such term
in Section 4.14.1 below.
	 
	 	1.2.30.	 	“IP” shall mean (i) all inventions, materials, compounds,
compositions, substances, methods, processes, techniques, know-how,
technology, data, information, discoveries and other results of whatsoever
nature, and any patents, copyrights, proprietary intellectual or industrial
rights directly or indirectly deriving therefrom, as well as provisionals,
patent applications (whether pending or not), and patent disclosures together
with all reissuances, continuations, continuations in part, revisions,
extensions, and reexaminations thereof; (ii) all trademarks, service marks,
copyrights, designs, trade styles, logos, trade dress, and corporate names,
including all goodwill associated therewith; (iii) any work of authorship,
regardless of copyrightability, all

 - 3 - 

 

	 	 	 	compilations, all copyrights; and (iv) all
trade secrets, confidential information and proprietary processes.
	 
	 	1.2.31.	 	“License” shall bear the meaning assigned to such term in Section
6.1 below.
	 
	 	1.2.32.	 	“Licensed Information” shall bear the meaning assigned to such
term in Section 6.1 below.
	 
	 	1.2.33.	 	“Licensed Product(s)” shall bear the meaning assigned to such
term in Section 6.1 below.
	 
	 	1.2.34.	 	“Major Countries” shall mean the United States of America,
Canada, the EU Market, China, Japan, Israel, Mexico, India, Australia and New
Zealand.
	 
	 	1.2.35.	 	“Manufacturing Know-how” shall bear the meaning assigned to such
term in Section 10.7 below.
	 
	 	1.2.36.	 	“Market Advantage” shall [***]
	 
	 
	 	1.2.37.	 	“Milestone” shall bear the meaning assigned to such term in
Section 8.1 below.
	 
	 	1.2.38.	 	“Milestone Payments” shall bear the meaning assigned to such term
in Section 8.1 below.
	 
	 	1.2.39.	 	“Net Sales” shall mean with respect to a Licensed Product, the
total gross amounts [***] in respect of such Licensed Product, as established in a
bona fide arms-length transaction with an unrelated third party, less the
following items (as they apply to such Licensed Product): (i) quantity and/or
cash discounts actually allowed or taken; (ii) customs, duties, sales and
similar taxes, if any, imposed on the Licensed Product, to the extent
applicable to such sale and included in the invoice in respect of such sale;
(iii) amounts actually allowed or credited by reason of rejections, return of
goods (including as a result of recalls), any retroactive price reductions or
allowances specifically identifiable as relating to the Licensed Product; (iv)
amounts incurred resulting from government mandated rebate programs (or any
agency thereof); (v) third party (a) rebates, (b) freight, postage, shipping
and applicable insurance charges, to the extent the same are separately

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 4 - 

 

	 	 	 	itemized on invoices and actually paid as evidenced by invoices or other
appropriate supporting documentation, and (c) chargebacks or similar price
concessions related to the sale of the Licensed Product; (vi) bad debts
deriving from Net Sales in respect of which Royalty Payments were paid to
Protalix pursuant hereto, (vii) royalties paid to third parties
[***] in respect of the use of such third party’s
intellectual property rights (provided that in no event shall the amounts
deducted in respect of such third party royalties under (vii) result in the
reduction of the Royalty Payments to Protalix to less than
[***] of the Net
Sales attributable to any particular Licensed Product, (without derogating
from any lower royalty rates as determined by Sections 8.2(a) or 8.2(b)
below), and (vi) reasonable quantities of samples, provided the quantity of
Licensed Product actually utilized for purposes of such samples shall not
exceed [***] of the volume of annual Licensed Product sales during any given
year during this Agreement. All of the foregoing shall be calculated in
accordance with U.S. GAAP.
	 
	 	 	 	[***]
	 
	 	 	 	In addition, the Net Sales shall be furthermore adjusted and reduced in the
event that a Licensed Product is sold as part of a Combination Product as set
forth in Section 8.4 hereto.
	 
	 	 	 	With respect to sales which are not at bona fide arms-length and/or are not in
the ordinary course of business, the term “Net Sales” shall mean the total
amount that would have been due in an arms-length sale made in the ordinary
course of business and according to the then current market conditions for such
sale or, in the absence of such current market conditions, according to market
conditions for sale of products similar to the Licensed Products. If Licensed
Products are sold or supplied in a currency other than United States Dollars
then the sum of Net Sales shall first be determined in the currency in
which such Licensed Products were invoiced and then converted into equivalent
United States Dollars at the middle market rate of such foreign currency as
quoted in the Financial Times at the close of business of the last business day
of the quarter with respect to which the payment is made.
	 
	 	1.2.40.	 	“Non-Platform IP” — shall mean all Licensed Information and Teva
IP, other than Platform IP.
	 
	 	1.2.41.	 	“Other IP” shall mean any and all IP developed within the
framework of the collaboration hereunder (including both the performance of
the Feasibility Program and the performance of Stage 2, in the event that Teva
exercises its option to have Stage 2 performed), which is neither Platform IP
nor Protein IP.
	 
	 	1.2.42.	 	“Platform IP” — shall mean Protalix’s existing and future
proprietary recombinant plant culture process and technologies directly
related to such process, and improvements thereto, as may be further developed
in the course

 

 			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 5 - 

 

of the collaboration, or otherwise, by or for Protalix, at any
time prior to the expiration of [***] following the First
Commercial Sale of the first Licensed Product. The list of patents and patent
applications included under the Platform IP, existing as of the date of
execution of this Agreement is attached hereto as Annex 1.2.42 (the “Platform
Patents”).

All additional patent applications/ patents that may be filed by or for Protalix
to cover portions of the Platform IP at any time prior to the expiration of
[***] following the First Commercial Sale of the first Licensed
Product, shall be immediately reported by Protalix to Teva and shall be included
in the term ‘Platform Patents’ as of the time of such report.

	 	1.2.43.	 	“Protalix Competitor” shall mean: [***]
	 
	 	1.2.44.	 	“Protein(s)” each of the two (2) therapeutic proteins as
selected by Teva and agreed upon by Protalix (such agreement not to be
unreasonably withheld, conditioned or delayed), expressed in plant
cell-expression system, to be described in Annex 1.2.44 hereto, as
might be substituted subject to the terms of this Agreement.
	 
	 	1.2.45.	 	“Protein IP” — shall mean any and all IP developed during the
collaboration hereunder (including both the performance of the Feasibility
Program and the performance of Stage 2, in the event that Teva exercises its
option to have Stage 2 performed), which relates specifically to the Proteins
and which is not Platform IP. Notwithstanding the foregoing, any patent(s)
related to the Platform IP that specifically
and directly and solely relates to one or both of the Proteins shall be
considered part of the Protein IP, and not Platform IP.
	 
	 	1.2.46.	 	“ROFL” shall bear the meaning assigned to such term in Section
14.1 below.
	 
	 	1.2.47.	 	“ROFO” “ROFO Notice” and “ROFO Period” shall bear the meanings
assigned to such terms in Section 3.2.1 below.
	 
	 	1.2.48.	 	“Royalty Payments” shall bear the meaning assigned to such term
in Section 8.2 below.
	 
	 	1.2.49.	 	[***]
	 
	 	1.2.50.	 	“Stage 2” shall bear the meaning assigned to such term in Section
3.4 below.
	 
	 	1.2.51.	 	“Stage 2 Notice” and “Stage 2 Notice Period” shall bear the
meaning assigned to such terms in Section 3.4 below.
	 
	 	1.2.52.	 	“Sublicence” shall mean any right granted, license given, or
agreement entered into, by Teva and/or its Affiliates to or with any other
person or entity

	 		
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 6 - 

 

	 	 	 	(whether or not such grant of rights, license given or
agreement entered into is described as a sublicence or otherwise), permitting
any use of the Licensed Information (or any part thereof) or any right to
research, develop, make, have made, register, import, manufacture, use, sell,
offer for sale, produce, sublicense, commercialize and/or distribute the
Proteins and/or the Licensed Products for any indication; and the term
“Sublicensee” shall be construed accordingly.
	 
	 	1.2.53.	 	“Teva Competitor” shall bear the meaning ascribed to such term in
Section 11.5 below.
	 
	 	1.2.54.	 	“Teva IP” shall bear the meaning assigned to such term in
Section 11.6 below.

	 	1.3.	 	In this Agreement, words importing the singular shall include the plural and
vice-versa and words importing any gender shall include all other genders and
references to persons shall include partnerships, corporations and unincorporated
associations.
	 
	 	1.4.	 	The words “including” and “includes” mean including, without limiting the
generality of any description preceding such terms.
	 
	 	1.5.	 	In the event of any discrepancy between the terms of this Agreement and any of
the Annexes hereto, the terms of this Agreement shall prevail.

2. General Scope 

	 	2.1.	 	The Parties hereby agree to collaborate in the development, and the
manufacturing of the Proteins, on the basis of the Platform IP.
	 
	 	2.2.	 	The collaboration in respect of the development of the Licensed Products shall
initially be carried out through the performance of the Feasibility Program.
Following completion of same, should Teva so elect at its sole and exclusive
discretion, the collaboration shall continue by way of the development of Licensed
Products.
	 
	 	2.3.	 	The commercialization of the Licensed Products shall be performed solely by
Teva (or any third party on its behalf in accordance herewith), without the
collaboration of Protalix, under the License granted to Teva hereunder.

	3.	 	The Collaboration

	 	3.1.	 	The Feasibility Program – Stage 1

	 	3.1.1.	 	Protalix shall carry out a feasibility program in respect of each
of the Proteins in accordance with the protocol and time schedule as agreed
between the Parties to be attached hereto within thirty (30) days of the
Effective Date as Annex 3.1.1 (the “Feasibility Program”). An outline of the
activities to be performed by Protalix under the Feasibility Program, as
currently envisaged, is attached hereto as Annex 3.1.1A. The Feasibility
Program will mainly consist of producing [***]. One (1) Protein shall be
agreed upon between the Parties, within thirty (30) days of the

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 7 - 

 

	 	 	 	Effective
Date, and shall be described in Annex 1.2.44 (the “First Protein”) and the
other Protein (the “Second Protein”) shall be selected by Teva by [***] following the execution hereof, and agreed upon by
Protalix, such agreement not to be unreasonably withheld.
	 
	 	3.1.2.	 	Protalix shall begin performing the Feasibility Program in respect
of the First Protein immediately after the First Protein is selected by the
Parties, and, shall begin performing the Feasibility Program in respect of the
Second Protein, as soon as practicable, but no later than four (4) weeks
following the selection of Second Protein by Teva and its approval by
Protalix, as aforementioned.
	 
	 	3.1.3.	 	Each Feasibility Program will be carried out by Protalix at its
sole cost and expense in accordance with a budget reasonably determined by it
in accordance with industry standards, and based on the Feasibility Program. A
Feasibility Program may be adjusted with the consent of the R&D Committee (as
defined below) from time to time. A non-binding estimate of the resources and
expenses that Protalix expects to dedicate to, and incur in the conduct of
each Feasibility Program (inclusive, inter alia, of the estimated costs of
FTEs and materials) will be submitted to the R&D Committee at the beginning of
each Feasibility Program and an updated non-binding estimate pertaining to the
remainder of the Feasibility Program shall be submitted twelve (12) months
following commencement of each Feasibility Program. Protalix shall keep
separate records of the expenses actually incurred by it in the conduct of
each Feasibility Program and shall provide Teva and the R&D Committee with
detailed quarterly reports of its expenses. For the avoidance of doubt, it is
clarified that any major deviation by Protalix from the activities set forth under a Feasibility Program shall require
the prior written approval of the R&D Committee. Any material increase in
the cost of the conduct of the Feasibility Program deriving solely from
an agreed change in the activities included in the Feasibility Program
will be discussed and negotiated in good faith between the management of
both Parties.
	 
	 	3.1.4.	 	Protalix shall complete each Feasibility Program within [***]. Any extension of such time period that may be
requested by Protalix, with respect to each or any Protein, must be approved
in advance and in writing by Teva, which approval shall not be unreasonably
withheld. For avoidance of doubt, Protalix shall bear all costs and expenses
related to the performance of the Feasibility Program until its completion
regardless of the term of its duration.
	 
	 	3.1.5.	 	At the end of each calendar quarter during the course of the
performance of each Feasibility Program, Protalix shall provide Teva with
periodic progress reports regarding the progress of such Feasibility Program,
in a form to be agreed in advance between the Parties.
	 
	 	3.1.6.	 	Teva’s representative(s) on the R&D Committee may, from time to
time, request updates regarding the progress of Stage 1, in addition to the
periodic progress reports, and Protalix shall provide any additional update
that Teva’s representative(s) on the R&D Committee may reasonably request.
	 
	 	3.1.7.	 	Not later than sixty (60) days after the completion of the
performance of

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 8 - 

 

	 	 	 	each Feasibility Program in respect of each Protein, Protalix
shall provide Teva with a written report detailing the results of such
Feasibility Program in respect of each Protein, in a form acceptable to Teva
(each, a “Final Feasibility Report”).
	 
	 	3.1.8.	 	After receipt by Teva of each Final Feasibility Report, if Teva
wishes to receive further information from Protalix it shall so advise
Protalix by written notice specifying such additional information requested
(the “First Notice”), to be delivered to Protalix no later than sixty (60)
days as of the date of provision to Teva of the Final Feasibility Report.
Protalix will provide such additional information within a reasonable time,
but not later than sixty (60) days following receipt of the First Notice (the
“Initial Response”). In the event that following receipt of the Initial
Response, Teva wishes to receive further information from Protalix, it shall
so advise Protalix by written notice specifying such additional information
requested (the “Second Notice”), to be delivered to Protalix no later than
forty five (45) days as of the date of provision to Teva of the Initial
Response. Protalix will provide such additional information within a
reasonable time but not later than forty five (45) days following receipt of
the Second Notice (the “Additional Response”). In the event that following
receipt of the Additional Response, Teva wishes to receive further information
from Protalix, it shall so advise Protalix by written notice specifying such
additional information requested (the “Third Notice”), to be delivered to
Protalix no later than thirty (30) days as of the date of provision to
Teva of the Additional Response. Protalix will provide such additional
information within a reasonable time but not later than thirty (30) days
following receipt of the Third Notice (the “Final Response”). In the
event that the Initial Response, together with the Additional Response
and the Final Response provide the full and complete information
reasonably requested by Teva, then following submission of the Final
Response Protalix shall not be required to provide any additional
information to Teva in connection with the Final Feasibility Report.
	 
	 	3.1.9.	 	Protalix shall NOT be entitled to subcontract its obligations to
perform the Feasibility Programs to any third party whatsoever without the
prior written approval of Teva, which approval shall not be unreasonably
withheld.
	 
	 	3.1.10.	 	Without limiting the generality of the second sentence of Section
16.6, the Parties hereby acknowledge that Protalix has not guaranteed that
Stage 1 will be successful or achieve any specific results at all or within
the specified time period.

	 	3.2.	 	Right of First Offer

	 	3.2.1.	 	Until the lapse of a [***] period from the Effective
Date or until the selection by Teva of the Second Protein, whichever comes
first (the “ROFO Period”) Protalix shall refrain from entering into an
agreement with any third party the purpose of which is the development or
commercialization of any [***] protein utilizing the Platform IP,
unless Protalix shall first offer Teva in writing to select such protein as
the Second Protein (the “ROFO” and the “ROFO Notice”, respectively). Upon
receipt of the ROFO Notice Teva will have the right, within thirty (30) days
of the date of the

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 9 - 

 

	 	 	 	ROFO Notice, to select such protein as the Second Protein,
by written confirmation of such selection which selection Protalix shall be
deemed as being in agreement with. Protalix shall immediately notify Teva in
writing of the commencement of any negotiations with any third party regarding
the development or commercialization of any [***] protein during the
ROFO Period, and any such notice shall be deemed as a ROFO Notice pursuant to
this Section 3.2.1, it being understood and agreed that Protalix shall not be
required to divulge the identity of such third party or any other detail of
such negotiations. The ROFO Notice shall in both cases be accompanied by any
Protalix’s available information in respect of such [***] protein.
	 
	 	3.2.2	 	For the avoidance of doubt, Protalix shall not be required to offer
any protein to Teva more than once pursuant to this Section 3.2.

	 	3.3.	 	Substitution of a Protein

The Parties acknowledge and declare that their joint goal is that the
performance of the Feasibility Program will result in the development of two
(2) Proteins (within the timeframe envisaged hereunder) suitable, in
technological and marketing terms, for implementation of Stage 2 (as such
term is defined below). In furtherance thereof, the Parties may, at
any time during the performance of a Feasibility Program, by mutual consent (which
consent shall not be unreasonably withheld by either Party), and following
the recommendation of the R & D Committee, decide upon the substitution of
the Protein in respect of which such Feasibility Program is being conducted
if the Parties are not satisfied with the results. Moreover, Teva, at its
sole discretion, shall be entitled to substitute the Protein(s) in respect of
which a Feasibility Program has been or is being conducted by another
protein, by instructing Protalix to cease the performance of a Feasibility
Program in progress, and to begin the performance of a Feasibility Program in
respect of a different protein to be selected by Teva as per the procedure
set out below, in each of the following events (i) during the first twelve
(12) months from the commencement of a certain Feasibility Program, for any
reason; or (ii) prior to the expiry of thirty (30) days after receipt by
Teva of the Final Feasibility Report, Initial Response, Additional Response
or Final Response (as the case may be), Teva reaches a decision that based on
scientific reasons it requires substitution of a certain Protein. Teva’s
right to substitution under (i) and (ii) above shall exist only once with
respect to each Protein, and Teva shall be required to propose two new
proteins, each of which must be Contractually Free (as such term is defined
below), and Protalix shall have the right to choose one of them. Following
such selection, such new protein shall become a Protein for the purposes
hereof, and Protalix shall begin the performance of the Feasibility Program
in respect of the replacement Protein as shall be agreed between the Parties
at Protalix’ sole cost and expense. In any event, the replacement of one
Protein with another as set forth in this Section shall be subject to the
refund by Teva of the direct costs actually incurred by Protalix in the
performance of the Feasibility Program, until the date of mutual consent as
to, or the notice of, replacement (as the case may be), and winding down of
the Feasibility Program in respect of the Protein that was replaced (provided

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 10 - 

 

that such winding down costs shall be mitigated by Protalix to the maximum
extent reasonably possible), which costs shall be evidenced by invoices and
other supporting documentation that shall be provided to Teva.

For the purposes of this Section, the term “Contractually Free” shall mean,
in respect of any protein, that no third party has been granted any rights by
Protalix in respect of such protein, whether pursuant to an agreement or a
term sheet or other similar legally binding document, that would preclude or
limit Protalix’s ability to grant Teva the rights granted hereunder if such
protein were to become a Protein.

	 	3.4.	 	Teva’s Option for Stage 2

Within two (2) months of the later of receipt by Teva of each Final Feasibility Program
Report, Initial Response, Additional Response or Final Response in conformance with
Section 3.1.8 above (if at all) (the “Stage 2 Notice Period”), Teva, at its sole
discretion, shall notify Protalix in writing in respect of each Protein, if it wishes
to enter into the product development stage in respect of such Protein (“Stage 2”) (the
“Stage 2 Notice”).

During the Stage 2 Notice Period Teva’s representatives shall have the right to visit
and audit Protalix’s facilities for the sole purpose of evaluating its interest in
entering
into Stage 2, at times to be coordinated in advance between the Parties.

In the event that Teva does not provide Protalix with the Stage 2 Notice during the
Stage 2 Notice Period with respect to any specific Protein, but provided that Protalix
furnishes all of the information duly requested by Teva pursuant to Section 3.1.8
above, then this Agreement shall expire forthwith with respect to such Protein in which
case, other than as to the obligations of confidentiality as set forth in Section 20
below and the obligation to return documentation as set forth in Section 15.6 below:
(i) Teva shall not be obligated in any manner towards Protalix with respect to such
Protein; and (ii) Protalix shall not be obligated in any manner towards Teva with
respect to such Protein.

4. Product Development — Stage 2 

	 	4.1.	 	In the event that Teva elects to exercise its option to initiate the
performance of Stage 2 of the collaboration as to one or both Proteins, Stage 2
shall be carried out by the Parties in accordance with Development Plans (defined
below) to be determined pursuant to this Section 4.
	 
	 	4.2.	 	Teva shall prepare preliminary development plans (the “Preliminary Plan(s)”),
in consultation with Protalix within [***] of Teva exercising its option
to initiate the Stage 2 collaboration. The Preliminary Plan(s) shall include
projected Licensed Product development activities, timelines and obligations of each
Party up to the completion of Phase I clinical trials in respect of the relevant
Protein.
	 
	 	4.3.	 	Stage 2 shall commence, as to each Protein (as applicable), immediately upon
the relevant Preliminary Plan being presented to the R&D Committee (or in its
absence to Protalix) which shall be given the opportunity to comment thereon prior
to implementation, provided that in no event shall such entitlement to comment

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 11 - 

 

	 	 	 	derogate in any way from the full and sole discretion of Teva in respect of all
aspects of the Preliminary Plan(s) (and the Development Plan(s)) and the performance
thereof.
	 
	 	4.4.	 	The Preliminary Plan shall be updated from time to time but not less often
than once every six (6) months, by Teva, in consultation with the R & D Committee,
as per the progress of the different development phases (the Preliminary Plan so
updated being referred to hereinafter as the “Development Plan(s)”). The
Development Plan shall incorporate detailed development activities in respect of the
Licensed Product for the upcoming phase. Teva, in consultation with Protalix will
consider and determine Phase II clinical trial target activities, timelines and the
Parties’ obligations, which will become specific obligations of the Parties.
Notwithstanding the foregoing, Teva may update the Development Plan, at Teva’s
discretion, in consultation with the R&D Committee, at any time and from to time, to
reflect progress made as per the Development Plan. Without derogating from any of
the above, the outline of the activities of the Parties under the Development Plan,
as currently envisaged, is attached hereto as Annex 4.4.
	 
	 	4.5.	 	The Development Plan shall specify the activities, timelines and division of
responsibilities between Teva and Protalix in respect of the performance of the
Stage 2 collaboration. Teva and Protalix shall each make commercially
reasonable efforts consistent with their respective normal business practices to
each pursue their obligations under the Development Plan, and shall each diligently
perform its tasks as set forth in the Development Plan. Without derogating from the
foregoing, in the course of the performance of Stage 2, Protalix shall be obligated
to provide Teva with manufacturing information as may be reasonably required by
Teva solely for the purpose of Teva’s pursuing clinical development, and obtaining
regulatory approvals for and commercializing, Licensed Products.
	 
	 	4.6.	 	At the end of each calendar quarter during the course of the performance of
Stage 2, each Party shall provide the other Party with periodic progress reports
regarding the progress of such Party’s activities under Stage 2, in a form to be
agreed between the Parties. Each Party may, from time to time, request updates
regarding the progress of the other Party’s activities during Stage 2, in addition
to the periodic progress reports, and pursuant to any reasonable request, the other
Party shall provide same.
	 
	 	4.7.	 	In addition, Protalix shall provide Teva, at Teva’s request, with reports, in
an agreed form, including financial reports in the format required by the Office of
the Chief Scientist (“CSO”) which Teva may be required to provide to the CSO in
order to obtain CSO support for Stage 2, in addition to the periodic progress
reports to be provided hereunder.
	 
	 	4.8.	 	Each Party shall perform its obligations under the Development Plan in
accordance with all applicable laws and regulations, and each Party shall procure
the receipt of all approvals and consents necessary for the performance of such
Party’s obligations under the Development Plan. Without derogating from the
foregoing, it is clarified that approvals and consents necessary for the performance
by Protalix of its portion of the Development Plan and specifically related to the
Protein but also usable by Protalix in respect of other proteins shall be procured
by Protalix and the costs of same shall be allocated between Teva and Protalix in
accordance with the relative use of same in respect of the relevant Protein.

 - 12 - 

 

	 	4.9.	 	Teva’s representatives shall have the right to visit and audit Protalix’s
facility where Licenced Product is manufactured, at times to be coordinated between
the Parties in advance, once Protalix commences the manufacture of clinical
quantities of Licensed Product, but not more often than twice every calendar year.
	 
	 	4.10.	 	Teva shall provide Protalix with copies of all regulatory filings and
approvals, investigational new drug (IND), chemistry manufacture and control (CMC)
files, new drug applications (NDA), drug master files, clinical protocols and
reports, and all modifications thereto, as well as material correspondence with
regulatory authorities. Teva shall keep Protalix currently informed about the
progress made towards obtaining regulatory approval of the Licensed Products in each
country and shall provide Protalix with written status reports on a quarterly basis.
Teva shall also notify Protalix, in writing, immediately upon the receipt of
regulatory approval of any Licensed Product in each country.
	 
	 	4.11.	 	No later than [***] prior to the commencement by Teva of Phase III
clinical trials in respect of the Licensed Product(s), Protalix shall provide to
Teva (or shall instruct the Escrow Agent to release to Teva) the Backup
Manufacturing File.
	 
	 	4.12.	 	Protalix shall not be entitled to subcontract all or part of its tasks under
the Development Plan, without Teva’s prior written consent. Should Protalix wish to
do so, Protalix shall so notify the R&D Committee and Teva in writing, and Teva
shall have the right, at its sole discretion (but shall not be obligated), to
perform such tasks as Protalix’s subcontractor, on the condition that Teva shall
perform same over a reasonable time period no longer than the time period that it
would take another reasonable third party to perform such task(s). For the sake of
clarity, in the event that Teva shall elect not to perform as Protalix’s
subcontractor, and Protalix shall use a permitted subcontractor that is not Teva,
Protalix shall bear all responsibility and liability vis-à-vis Teva arising from the
performance by such subcontractor. To the extent Teva wishes to subcontract any part
of its tasks under the Development Plan to any third party, it shall so notify the
R&D Committee, it being understood and agreed that no subcontract by Teva shall be
made to a Protalix Competitor, except if and to the extent that Protalix is not
capable of performing the same service for Teva at a competitive market price. For
the sake of clarity and without limiting the foregoing, in the event that Teva shall
use a subcontractor for the performance of any of its obligations hereunder, Teva
shall bear all responsibility and liability vis-à-vis Protalix arising from the
performance by such subcontractor.
	 
	 	4.13.	 	The Parties hereby acknowledge that neither Party has guaranteed that Stage 2
will be successful or achieve any specific results or that any regulatory approvals
shall be granted with respect to the Licensed Products.
	 
	 	4.14.	 	From the commencement of the performance of Protalix’s obligations under
Stage 2, Teva shall bear all actual costs incurred or expended by Protalix directly
related to the performance of Protalix’s activities included in Stage 2, according
to the budget proposed by Protalix and pre-approved in writing by Teva (the
“Budget”), as follows:

	 	4.14.1.	 	Protalix’s direct development expenses and manufacturing costs for the performance of Protalix’s
share of the development activities (including clinical material manufacturing), on a [***] basis
which shall include, [***], shall be reimbursed on a [***] basis, as follows:

	 	a.	 	[***]
	 
	 	b.	 	[***]

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 13 - 

 

	 	4.14.2.	 	All of Protalix’s out-of-pocket expenses incurred in relation to the performance of the development
activities and the achievement of development milestones (“External Development Expenses”), shall
be reimbursed on a [***] basis [***].

	 	4.15.	 	The amounts of the Budget described above shall be paid by Teva every [***]
months on a [***] rolling basis, whereby [***] of the relevant Budget for each [***]
shall be paid upfront at the beginning of such [***] period and the balance shall be
paid at the end of the relevant [***], unless only part of the relevant tasks were
carried out during such period, in which case the balance shall be adjusted
accordingly. All payments shall be made against receipt of a proper tax invoice.
	 
	 	4.16.	 	For the avoidance of doubt, it is clarified that (i) any in-licensing of
third party technology by Protalix for the purposes of the performance of the
Feasibility Programs or the Development Programs (or any one of them) and/or for the
incorporation of such third party technology into the process of the development or
manufacture of the Proteins and/or (ii) any use of third party technology (including
that of [***] already licensed to Protalix) by Protalix in the
performance of the Feasibility Programs (or any one of them) or in the development
or manufacture of the Proteins, shall require the prior written agreement of Teva,
and shall not be in-licensed or used, as applicable, in the event that such prior
written agreement of Teva is not provided. Payments to third parties in respect of
such licenses shall be borne and paid by [***]. For the avoidance of doubt,
any such approval by Teva rendered in the course of a Feasibility Program, shall
continue to apply during the Development Program and thereafter for as long as the
third party technology is in use in relation to Licensed Products commercialized by
Teva, its Affiliates, Sublicensees or Further Sublicensees, and may not be retracted
by Teva.
	 
	 	4.17.	 	Protalix shall be obligated to manufacture the Proteins, both for development
and commercial purposes for the sole consideration provided in Section 4.14 above
and 10 below, in such quantities as shall be set forth in the Feasibility Program
(during Stage 1) and the Development Plan (during Stage 2), and thereafter, as per
orders placed by Teva pursuant to a separate manufacturing and supply agreement (the
“Supply Agreement‘) to be entered into between the Parties by no later than the
initiation of Phase III regulatory clinical trials in respect of a Licensed Product.
Protalix shall manufacture the Proteins in accordance with applicable regulatory
requirements (such as GMP and GLP, as determined by Teva in consultation with
Protalix) and shall be fully responsible for its manufacturing activities (and those
of

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 14 - 

 

	 	 	 	any third party on its behalf). The Supply Agreement shall govern the procedures
for ordering and deliveries, lead time for deliveries, quality assurance,
specifications and all other matters related to the manufacture and supply of the
API by Protalix in accordance with the relevant regulatory requirements as shall be
determined by Teva in consultation with Protalix, reflecting the commercial terms
set out in Section 10.4 hereunder. Key elements of the Supply Agreement shall be set
forth in Annex 4.17 which shall be attached hereto within thirty (30) days
of the Effective Date.
	 
	 	4.18.	 	Any deviation from the approved Budget for Stage 2 shall require notification
to Teva in advance, provided that any such deviation in excess of
[***] shall also require the prior approval of Teva.

5. Research and Development Committee

	 	5.1.	 	The Parties shall form a Research and Development Committee (the “R & D
Committee”), that shall be active for the duration of the Feasibility Program and the
Development Plan. During Stage 1 the R & D Committee shall have the charter to adjust
and amend the Feasibility Program (per Protein), as required for scientific or
technological reasons. During Stage 2 the R & D Committee shall monitor the
performance of the Development Plans, the research and other activities being
conducted thereunder, and shall issue its recommendations in writing to the Parties,
but shall have no decision making authority. The R&D Committee shall be comprised of
four (4) members, having one vote each, of which two (2) shall be appointed by each
Party, including one co-chairperson appointed by each Party. Only employees of the
Parties can be appointed to serve on the R&D Committee. The R&D Committee shall meet
periodically (but in any event no less than quarterly) during the performance of the
Feasibility Program and Development Plan.
	 
	 	 	 	In the event that, during the term of a Feasibility Program, the members of the R&D
Committee cannot agree on an issue within the scope of its authority within thirty
(30) days of its initial consideration, the matter shall be referred by either
co-chairpersons in writing to one (1) expert, the identity of whom shall be mutually
agreed upon, for a reasoned determination in writing. In the event that, during the
term of the Development Plan, the members of the R&D Committee cannot agree on a
recommendation to be made to Teva, then the members appointed by Teva shall have a
casting vote in respect of such recommendation.
	 
	 	5.2.	 	At each R&D Committee meeting, at least one (1) member appointed by each Party
present in person or by telephone shall constitute a quorum. Each Party shall have
equal voting power, whether represented by one or two Committee members, on all
matters before the R&D Committee.

6. License Grant

	 	6.1.	 	Subject only to the provision of the Stage 2 Notice by Teva, Protalix hereby
grants Teva, and Teva hereby accepts from Protalix, an exclusive world-wide license
under the Platform IP, the Protein IP and the Other IP owned by or licensed to
Protalix (collectively, the “Licensed Information”) to research, develop, make, have
made, register, import, manufacture, use, sell, offer for sale, produce, sublicense,
commercialize, distribute the Proteins and/or pharmaceutical products embodying,

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 15 - 

 

	 	 	 	based on or using the Proteins (the “Licensed Products”) for all indications (the
“License”) and for no other purposes whatsoever.

	 	6.1A	 	To the extent that the Parties shall mutually agree that any Additional Patents are
reasonably required to be licensed to Teva in order for Teva to commercialize any
Licensed Product(s), then the same shall be added to the list of the Platform Patents and
as of such time shall be deemed as being covered by the License hereunder, as part of the
Platform IP, provided that at the relevant point in time an exclusive license in respect
of such Additional Patent has not already been granted to a third party by Protalix, it
being understood and agreed, however, that any such Additional Patents may not be
sub-licensed by Teva on a stand alone basis.

	 	6.2.	 	From the Effective Date and at all times prior to [***] with respect to any particular Protein, Protalix shall not, without
Teva’s prior written consent, grant or enter into any agreement, arrangement or
commitment according to which a third party is granted any rights which may derogate
from or hinder Teva’s ability to exercise Teva’s option to obtain the License.

	 	6.3.	 	Teva shall have the right to grant (whole or partial) Sublicenses to third
parties (and such third parties shall be entitled to grant further Sublicenses
(each, a “Further Sublicense” and the term “Further Sublicensee” shall be construed
accordingly) and so on under the License, on terms and conditions consistent with
the terms of this Agreement and Teva shall be entitled to determine the commercial
terms of any such Sublicense, all provided that under no circumstances may any
Sublicense or Further Sublicense be granted to a Protalix Competitor, unless such
Sublicense or Further Sublicense is not granted in respect of the core technology of
Protalix (for example, but without limitation, a Sublicense or Further Sublicense
may be granted in respect of the marketing and/or distribution of the Licensed
Products(s) even to a Protalix Competitor), and provided further that all of
Protalix’s rights hereunder shall be ensured and, without limiting the generality of
the foregoing, that, with respect to each Sublicense or Further Sublicense
agreement: (i) Teva notifies Protalix immediately upon signature thereof, and
provides Protalix with the name of the Sublicensee or Further Sublicensee and the
scope and territory of the Sublicense or Further Sublicense; (ii) each such
Sublicense and Further Sublicense agreement (a) provides that the Sublicense or
Further Sublicense thereunder shall immediately terminate upon termination of the
License hereunder for any reason, and (b) restricting the right to grant a Further
Sublicense to a Protalix Competitor. The grant of any Sublicenses and Further
Sublicenses shall not derogate from the rights of Protalix and/or the obligations of
Teva under this Agreement. Without limiting the foregoing or any of Teva’s
obligations hereunder relating to the grant of Sublicenses or Further Sublicenses
pursuant hereto, Teva shall be entitled to conduct or to perform any activity in
respect of the Licensed Products by means of any third party sub-contractor, and
such conduct shall not be considered to be a grant of a sublicense, provided it
shall notify the R&D Committee and/or Protalix of any such subcontract and provided
further that under no circumstances may Teva subcontract any of its tasks or
obligations hereunder to a Protalix Competitor unless such subcontract is made not
in respect of the core technology of Protalix (i.e. Teva shall be entitled to
conduct marketing or distribution activities through subcontractors which are
Protalix Competitors). For the sake of clarity and without limiting the foregoing,
in the event that Teva shall use a subcontractor, Teva shall bear all responsibility
and liability vis-à-vis Protalix arising from the performance by such subcontractor.

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 16 - 

 

7. Commercialization of Licensed Products

	 	7.1.	 	Teva undertakes, at its own expense, to make such commercially reasonable
efforts to commercialize the Licensed Products as are consistent with the commercial
efforts generally applied to products of similar potential at similar stages in
their life cycles, by Teva.
	 
	 	7.2.	 	Teva shall provide Protalix with a non-binding sales forecast for each of the
Major Countries, in writing, in respect of each Licensed Product, by no later than
[***] prior to the anticipated date of the first regulatory approval in
respect thereto. Such report shall be updated by Teva, in writing, on
a [***] basis. Moreover, each sales forecast shall be accompanied by a report of Teva’s
and its Affiliates launch dates and main regulatory filings on a [***] basis
with respect to the Licensed Products. Teva shall also provide Protalix with similar
information with regard to such launch dates and filings in territories in which
Sublicensees and Further Sublicensees have conducted similar activities, to the
extent available to Teva.
	 
	 	7.3.	 	For the removal of doubt, nothing contained in this Agreement shall be
construed as a warranty by Teva that any efforts to be exerted by Teva in connection
with this Agreement, including without limitation any development or any
commercialization to be carried out by it in connection with this Agreement, will
actually achieve their aims or any other results or succeed, and Teva makes no
warranties whatsoever as to any results to be achieved in consequence of the
carrying out of any such development, commercialization, efforts or activities.
Furthermore, Teva makes no representation to the effect that the commercialization
of the Licensed Products, or any part thereof, will succeed, or that it shall be
able to sell the Licensed Products in any quantity.

8. Milestones and Royalty Payments 

	 	8.1.	 	In consideration for the grant of the License, Teva shall make the following
milestone payments to Protalix, upon achievement of the relevant
milestones on a [***] basis (each, a “Milestone”) (the “Milestone Payments”):

	 	8.1.1	 	with respect to the [***] Licensed Product that shall be approved for
marketing by the FDA or the EMEA based on a certain Protein (the “[***] Licensed
Product”):

	 	(a)	 	Upon receipt of marketing authorization approval for a [***]
Licensed Product by the first to approve same of either the FDA or the EMEA -
[***].
	 
	 	(b)	 	Upon the achievement by Teva of aggregate Net Sales of [***]
worldwide per such [***] Licensed Product at any given time, [***] on which the
aforementioned [***] Licensed Product is based in the US or in the EU Market,
during at least [***].

	 	8.1.2	 	with respect to the [***] Licensed Product (as defined below) that shall be
approved for marketing by the FDA or the EMEA based on a certain Protein:

	 	(a)	 	Upon receipt of marketing authorization approval for a [***]
Licensed Product by the first to approve same of either the FDA or the EMEA -
[***].
	 
	 	(b)	 	Upon the achievement by Teva of aggregate Net Sales of [***]
worldwide per such [***] Licensed Product at any given time, [***] on which the
aforementioned [***] Licensed Product is based in the US or in the EU Market,
during at least [***].

[***] of the aforementioned sums of [***] (in respect of both the [***] Licensed Product and
the [***] Licensed Product) shall be considered to have been paid on account of Royalty
Payments pursuant to Section 8.2 in respect of such [***] Licensed Product and [***]
Licensed Product respectively, such that amounts payable by Teva hereunder as Royalty
Payments in respect of such [***] Licensed Product and [***] Licensed Product respectively
shall be reduced by [***]. For the avoidance of doubt, it is clarified that, in respect of
each of such [***] Licensed Product and [***] Licensed Product respectively, following the
payment of said [***], Teva shall temporarily cease making Royalty Payments in respect of
such [***] Licensed Product or [***] Licensed Product, as applicable and shall only actually
begin making such Royalty Payments again from the first dollar received in Net Sales from
such [***] Licensed Product or [***] Licensed Product, as applicable, exceeding the amount
of Net Sales applicable to the payment of [***] in Royalty Payments.

[***]

For clarification, Teva shall not make any Milestone Payments for additional Licensed Products
beyond the [***] and [***] Licensed Products with respect to each Protein, i.e. no more than [***]
Milestone Payments in the aggregate.

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 17 - 

 

	 	8.2.	 	In addition, in consideration for the grant of the License, Teva shall,
throughout the Royalty Term (as such term is defined below), pay to Protalix
royalties at the following rates on annual Net Sales, during each calendar year in
respect of each Licensed Product, on a [***] (the “Royalty Payments”), as specified in this Section 8.2 below:

	 	(a)	 	[***] of Net Sales in the calendar year on the portion of annual Net Sales for the
relevant Licensed Product up to [***] of Net Sales during the time that [***];
	 
	 	(b)	 	[***] of Net Sales in the calendar year on the portion of annual Net Sales for the
relevant Licensed Product exceeding [***] and up to [***] of Net Sales during the time that
[***];
	 
	 	(c)	 	[***] of Net Sales in the calendar year on the portion of annual Net Sales for the
relevant Licensed Product exceeding [***] and up to [***] of Net Sales during the time that
[***];
	 
	 	(d)	 	[***] of Net Sales in the calendar year on the portion of annual Net Sales for the
relevant Licensed Product exceeding [***] and up to [***] of Net Sales during the time that
[***]; and
	 
	 	(e)	 	[***] of Net Sales in the calendar year on the portion of annual Net Sales for the
relevant Licensed Product exceeding [***] of Net Sales during the time that [***].

For the avoidance of doubt, it is hereby clarified that the [***] Royalty Payments due to
Protalix on account of Teva having achieved [***] shall apply only to that certain market in
which the [***] exists and for the duration of such existence. An example of the amount of
Royalty Payments to be made is given in Annex 8.2 hereto.

	 	8.3.	 	It is further clarified that in the event of [***] in at least one country in the EU Market, then
all countries of the EU shall be considered as territories in which [***] and the Royalty Payments
shall be computed accordingly; and for so long as there exists a [***] in ALL the countries of the
EU Market, then all countries of the EU shall be considered territories in which [***] and the
Royalty Payments shall be computed accordingly.

	 	8.4.	 	Notwithstanding the foregoing, in the event that any
[***] is sold
in the form of a Combination Product, then the proportion of such Combination
Product to

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 18 - 

 

	 	 	 	be attributed to Net Sales that are subject to the Royalty Payments (the
“Relevant Proportion”) shall be calculated as
provided below.

Provided that both active ingredients of the Combination Product are sold on a
stand-alone basis at the time in question, the Relevant Proportion
shall be as follows: [***], where A is the Net Sale price of the Protein-based component of the Licensed
Product sold separately, and B is the Net Sale price of the other
component sold separately.

[***]

In the event that the components of the Combination Product are not each sold on a stand-alone
basis at the time in question, the fraction above shall be calculated using the reasonably
estimated commercial value of each component. Any such estimates shall be determined using
criteria to be mutually agreed upon by the Parties.

For the purposes of determining Royalty Payments on a Combination Product, Net Sales shall be
determined by multiplying the actual Net Sales of such Combination Product by the Relevant
Proportion, and Teva shall make Royalty Payments to Protalix accordingly (for example — with
respect to the said demonstrated numbers the Royalty Payments shall be applied only to [***] out of
[***] Net Sales of the Combination Product).

For the avoidance of doubt, deductions from Net Sales pursuant to Section 1.2.39 (vii) (i.e. based
on payments for third party’s IP) shall not be made if triggered solely by the additional component
which is part of the Combination Product.

	 	8.5.	 	Payments to Protalix pursuant to this Section 8 will be due and payable
hereunder until the expiration of [***]years after the First Commercial Sale in any
country calculated on [***] basis (in
each case, the “Royalty Term”).

	 	8.6.	 	Following the expiry of the Royalty Term, [***], Teva
shall have a fully paid up license to continue to exploit the License without
having to make Royalty Payments with respect thereto.

9. Payment Terms and Reporting in Respect of the License

	 	9.1.	 	As of the achievement of the first Milestone pursuant to Section 8.1.1 above,
and for the duration of the Royalty Terms, Teva shall submit to Protalix, no later
than [***] after the end of each [***], [***] reports
setting out all amounts owing to Protalix in respect of the [***] to
which the report refers, and with respect to each Licensed Product, (i) the Net
Sales [***],
including a breakdown of Net Sales according to country and currency of sales, (ii)
amounts deducted as royalties to third parties pursuant to Section 1.2.39(vii),
(iii) total Milestone Payments and Royalty Payments due to Protalix in respect of
such [***] or, if no such payments are due to Protalix in respect of such
[***], a statement that no payments are due; and (iv) any calculations
made in relation to Combination Products. Teva shall submit to Protalix, by no
later than [***] after the end

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 19 - 

 

of each [***], an [***] report
setting out any adjustments in Royalty Payments pursuant to Section 9.2A. Each such
report shall be signed by the relevant financial executive of the Global Products
division of Teva.

All such reports, as well as all other reports provided hereunder, shall be treated as
Confidential Information pursuant to Section 20 below.

	 	9.2.	 	Amounts payable to Protalix in terms of Section 8 shall be paid to Protalix
(i) in respect of Royalty Payments, on a [***] basis, and no later than [***] after the end of each [***],
commencing with the first
[***] in which Net Sales are made, (ii) in respect of Milestone Payments,
within [***] following the achievement of the applicable Milestone.
	 
	 	9.2A	 	Notwithstanding, the [***] payments of Royalty Payments shall be paid based on
the assumption that no Market Advantage exists. Not later than [***] following the end
of a [***], Teva shall pay Protalix the additional nominal amounts of Royalty
Payments due in the event Market Advantage existed during such [***].
	 
	 	9.3.	 	Each payment due to Protalix hereunder shall be paid by wire transfer of
immediately available funds to an account designated by Protalix in writing.
	 
	 	9.4.	 	Teva shall maintain and shall cause its Affiliates to maintain, complete and
accurate records of Licensed Products sold under this Agreement, any amounts payable
to Protalix in relation to such Licensed Products and which records shall contain
information to reasonably permit Protalix to confirm the accuracy of any payments
made to Protalix. Teva shall retain and shall cause its Affiliates to retain such
records relating to a given calendar year for at least
[***] after the
conclusion of that calendar year, during which time Protalix shall have the right,
at its expense, to cause an independent, certified public accountant to inspect such
records during normal business hours for the sole purpose of verifying any payments
delivered under this Agreement. Such accountant shall not disclose to Protalix any
information other than information relating to the accuracy of reports and payments
delivered under this Agreement. In the event that any audit performed under this
Section 9.4 reveals an underpayment in excess of [***]in any calendar year, and if
such underpayment is proven to the satisfaction of a mutually agreed external
auditor (it being agreed that absent such mutual agreement as to the identity of the
auditor within thirty (30) days of a Party’s written notice to the other Party that
it wishes to have such external auditor appointed, the external auditor shall be one
of the ‘big four’ accounting firms), then Teva shall bear the full cost of such
audit. Protalix may exercise its rights under this Section only once every year and
only with reasonable prior notice to Teva, and the relevant Affiliate and subject to
prior coordination. Any such audit shall be made during Teva’s or the relevant
Affiliate’s normal business hours and shall not unreasonably interfere with the
business of Teva or the relevant Affiliate, and shall be completed within a
reasonable time. Teva shall promptly transfer to Protalix any payment due pursuant
to such auditor’s audit. Such payment shall bear interest as set forth in Section
23.17.
	 
	 	9.5.	 	Without derogating from the provisions of the preceding Section 9.4, Protalix
shall have the right to request that Teva inspect records of Licensed Products sold
under this Agreement by Sublicencees and Further Sublicensees, for the sole purpose
of verifying any payments delivered under this Agreement, in which case Teva shall
exert its reasonable commercial efforts to perform such audit. In the event that any
audit performed under this Section 9.5 reveals an underpayment in excess of [***],

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 20 - 

 

	 	 	 	and if such underpayment is proven to the satisfaction of a mutually agreed external
auditor (to be appointed in accordance with the procedure set out in Section 9.4
above), then Teva shall bear the full cost of such audit. In any other event (of
overpayment or underpayment of less [***], Protalix shall bear the full cost of such
audit. Protalix may exercise its rights under this Section only once every year.
Teva or Protalix, as applicable, shall immediately pay to the other Party any
underpayment or overpayment together with interest provided in Section 23.17 below.
	 
	 	9.6.	 	Protalix shall maintain, and shall cause its Affiliates to maintain, complete
and accurate records of both its Internal Expenses and External Development
Expenses, as well as records of costs incurred in the performance of each
Feasibility Program (for the event that Teva reimburses Protalix for same pursuant
to the substitution of a Protein), which records shall contain information to
reasonably permit Teva to confirm the accuracy of any payments made to Protalix.
Protalix and/or its Affiliates shall retain such records relating to a given
calendar year for at least seven (7) years after the conclusion of that calendar
year, during which time Teva shall have the right, at its expense, to cause an
independent, certified public accountant to inspect such records during normal
business hours for the sole purpose of verifying any payments delivered under this
Agreement. Such accountant shall not disclose to Teva any information other than
information relating to the accuracy of reports and payments delivered under this
Agreement. In the event that any audit performed under this Section 9.6 reveals an
overpayment in excess of [***]in respect of any Protein, and if such overpayment is
proven to the satisfaction of a mutually agreed external auditor (to be appointed
in accordance with the procedure set in Section 9.4 above), then Protalix shall
bear the full cost of such audit and shall promptly pay to Teva such overpayment
together with interest as provided in Section 23.17 below. Teva may exercise its
rights under this Section only once every year and only with reasonable prior
notice to Protalix, and subject to prior coordination. Any such audit shall be made
during Protalix’s or the relevant Affiliate (as applicable) normal business hours
and shall not unreasonably interfere with the business of Protalix or the relevant
Affiliate (as applicable) and shall be completed within a reasonable time.

10. Bulk (API) Manufacturing Terms

	 	10.1.	 	Notwithstanding Section 6 above, Protalix shall retain the exclusive right to
manufacture the API and to continuously supply same to Teva and its Affiliates,
Sublicensees and Further Sublicensees, for the Licensed Products, during the first
[***] years following the First Commercial Sale of the first Licensed Product on a
per Protein basis (the “Exclusive Manufacturing Term”). Teva shall be responsible
for the formulation of the API into finished Licensed Product. Without derogating
from any other visit and audit right under this Agreement, as from [***]
prior to the expected commencement of the Exclusive Manufacturing Term, Teva’s
representatives shall have the right to visit and audit Protalix’s facilities where
the API is being manufactured, during normal business hours, and following prior
coordination with Protalix.
	 
	 	10.2.	 	Following the expiry of the Exclusive Manufacturing Term, Teva shall have the
right to manufacture the API [***] in its own facility or elsewhere, or through any third party which is not a
Protalix Competitor, at its sole discretion, subject to the appropriate undertakings
by the transferee of non-disclosure and non-use other than the supply to Teva and
its

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 21 - 

 

	 	 	 	Affiliates, Sublicensees and Further Sublicensees, and shall use the
Manufacturing Know-how (as such term is defined below) solely for such purpose.
	 
	 	10.3.	 	Without derogating from the above, Teva may elect, at its sole discretion, to
continue receiving Protalix’s manufacturing services after expiration of the
Exclusive Manufacturing Term. In such event, Protalix undertakes to perform such
manufacturing services, for the sole consideration set forth in Section 10.4
hereinafter.
	 
	 	10.4.	 	As of the First Commercial Sale, Teva shall pay Protalix consideration based
on the actual direct cost of the manufacturing of the API incurred by Protalix to be
calculated pursuant to the Supply Agreement as shall be mutually
agreed [***]:

	 	10.4.1.	 	[***].
	 
	 	10.4.2.	 	[***].

In addition, as of the beginning of the Exclusive Manufacturing Term and as long as [***], Teva
shall pay Protalix [***] in relation to the manufacturing of the API and pre-approved by Teva,
[***] (“External Manufacturing Expenses”). External Manufacturing Expenses shall be reimbursed on
a [***] basis, [***].

	 	10.5.	 	Notwithstanding the foregoing, in the event that the annual payments to
Protalix that consist of the [***] (calculated according to Section
10.4 above) plus the Royalty Payments on a [***] basis during any given
calendar year (the “Annual Protalix Payment”), shall exceed the amount of [***] of
the aggregate amount of annual Net Sales in such calendar year on a [***]
basis (the “Ceiling Amount”), then the Annual Protalix Payment, in respect of the
[***], shall be reduced to an amount equal to the Ceiling Amount,
provided that in no event shall the Annual Protalix Payment in respect of the
[***], be reduced to an amount less than [***] calculated on the
basis of [***]. Any over payment by Teva shall be set-off, by written notice from
Teva to Protalix, detailing the calculation of such over-payment, from the upcoming
Royalty Payment due to Protalix hereunder.
	 
	 	10.6.	 	The Parties hereby acknowledge and agree that a back-up manufacturing
facility should be available in respect of the Proteins. Not later than six (6)
months prior to the commencement of Phase III clinical trials to be performed in
respect of the First Licensed Product on a per Protein basis, the Parties shall
mutually agree on the site at which such back-up manufacturing facility shall be
located, and the Party by whom such facility shall be established.

	 	10.7.	 	(A) Protalix shall transfer, on a per-Protein basis, to an agreed third party
(the “Escrow Agent”), by not later than date of the completion of Phase I (last
patient out) as set forth in the Development Plan, a complete file (the “Back-Up
Manufacturing File”) consisting of all engineering schemes, standard operating
procedures, protocols, plans, master manufacturing file, know how and any other
information, tangible or intangible, whether in writing, electronic form or
otherwise, and any updates thereof, which is reasonably necessary for Teva in

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 22 - 

 

order
to establish its own internal manufacturing facility and manufacture the API (the
“Manufacturing Know-how”). Concurrently with the transfer of the Back-Up
Manufacturing File to the Escrow Agent, a copy of the table of contents of such file
shall be transferred to the R&D Committee. Teva may request, based on such table of
contents, that the Back-Up Manufacturing File be reviewed by a mutually agreed
industry expert (the “Industry Expert”) who may recommend in writing that the file
be supplemented, as may be reasonably required and Protalix shall supplement such
file as recommended within sixty (60) days
from the receipt by Protalix of such written recommendation. The Industry Expert
shall be bound by confidentiality undertakings to Protalix no less stringent
than those contained in Section 20 hereof and shall not disclose to Teva any
information relating to or contained in the Back-Up Manufacturing File. The
Industry Expert shall sign a non-disclosure agreement to such effect.

(B) Subject to the terms of this Section 10.7(B), the Escrow Agent shall be
authorized to release the Back-Up Manufacturing File to Teva, solely upon the terms
and conditions set out in a tri-party agreement to be executed between the Parties
and the Escrow Agent, in the form to be attached hereto within thirty (30) days of
the Effective Date hereof (the “Escrow Agreement”). Such Escrow Agreement shall
determine that the Back-Up Manufacturing File shall be released to Teva upon the
earlier of: (i) [***]; (ii) the occurrence
of a material breach by Protalix of its manufacturing obligations hereunder, which
breach is not rectified within sixty (60) days of receipt by Protalix of Teva’s
written notice specifying the breach; and (iii) the grant of a winding-up order or
the appointment of a receiver in respect of Protalix, or the grant of an attachment
order on all, or a substantial portion of, Protalix’s assets, which is not set aside
within ninety (90) days of the issuance thereof. The Back-Up Manufacturing File as
may be duly released to Teva pursuant to the Escrow Agreement may be utilized by
Teva solely for the establishment and operation of a facility for the manufacture of
the API. Following release of the Back-Up Manufacturing File to Teva, on the grounds
stated in (ii) or (iii) above, Teva shall be entitled to manufacture the API also
through a Protalix Competitor.

(C) Teva shall reimburse Protalix, for its reasonable expenses directly incurred and
associated with the preparation by Protalix of the Back-Up Manufacturing File for
submission to the Escrow Agent and for its costs associated with the services of the
Escrow Agent and the Industry Expert pursuant hereto (pursuant to invoices submitted
by the Escrow and Industry Expert and paid by Protalix). 

11. Intellectual Property Rights 

	 	11.1.	 	The Parties agree that, as between the Parties, Protalix does and shall own
all rights, title and interest in and to the Platform IP. The Parties acknowledge
that certain of the Platform IP that might be developed by or for Protalix or a
subsidiary of Protalix (if such shall exist) following the Effective Date may be
subject to contractual limitations vis-à-vis third parties. Such limitations (which
by their nature, would apply to the Proteins and/or the Licensed Products) shall
apply to Teva only if and to

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 23 - 

 

	 	 	 	the extent Teva shall approve them in writing in
advance. Otherwise, Protalix shall be fully responsible for such contractual
limitations whether monetary or other.
	 
	 	11.2.	 	In the event that during the collaboration hereunder, any subsidiary of
Protalix or any company with which Protalix merges (if such shall exist) shall
generate or own any IP that if generated or owned by Protalix would have been
considered part of the Licensed Information hereunder, then Protalix shall
immediately notify Teva of such IP and shall act immediately and ensure that such IP
shall be licensed to Protalix (or directly to Teva) and will become part of
the Licensed Information, licensed to Teva as provided hereunder, at no additional
cost to Teva. Such IP shall be classified as Platform IP, Protein IP or Other IP in
accordance with the terms hereof as if it had been generated by Protalix in the
first place.
	 
	 	11.3.	 	All rights, title and interest in and to the Protein IP and Other IP
developed during the performance of the Feasibility Program, will be owned by
Protalix (“Protalix’s Protein and Other IP”). For avoidance of doubt, Protalix’s
Protein and Other IP will be considered part of the Licensed Information, and as
such, covered by the License hereunder.
	 
	 	11.3A	 	In the event that there is any portion of Platform IP that specifically and
directly relates (but does not solely relate) to one or more of the Proteins, and
Protalix shall seek patent protection in respect of such portion of the Platform IP,
then, to the extent possible: the Parties shall co-operate in order that the patent
protection sought shall be filed in a manner that will split/ distinguish between
patents covering Platform IP that solely relates to the Proteins and other Platform IP.
The patent applications/ patents filed in respect of Platform IP that solely relates to
the Proteins(s) shall be considered part of the Protein IP, and not Platform IP.
	 
	 	11.4.	 	Notwithstanding the above, in the event that a Change of Control of Protalix
is effected following the commencement of Stage 2, such that a Teva Competitor
acquires Control of Protalix, Teva shall have the right, at its sole discretion, to
receive an assignment of all Protalix Protein and Other IP without any assignment
fee. Protalix’s Protein and Other IP so assigned to Teva shall be treated hereunder
as Teva IP (as defined below) for all intents and purposes, provided however that
the economic benefits to Protalix under this Agreement, including inter alia, its
right to receive Royalty Payments and Milestone Payments, shall not be diminished as
a result of such assignment, in any way.
	 
	 	11.5.	 	A “Change of Control” means (i) the sale of all or substantially all of the
assets of Protalix, or (ii) any transaction between Protalix or its shareholders and
another entity/ies as a result of which another company/ies, or another company/ies’
ultimate shareholder/s, directly or indirectly shall own more than fifty percent
(50%) of the shares of Protalix or its successor, or has/ve the power to elect more
than half of Protalix’s or its successor’s directors. A
“Teva Competitor” means [***].
	 
	 	11.6.	 	All Protein IP and Other IP developed as of the date on which Teva provides
the Stage 2 Notice, by or for Protalix, jointly by or for both Parties, or by or for
Teva, shall be exclusively owned by Teva, and Teva shall have all right, title and
interest thereto (the “Teva IP”).

	 		
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 24 - 

 

	 	11.7.	 	Teva hereby grants Protalix a non-exclusive, royalty-free, perpetual license
to use such portion of the Other IP included in the Teva IP that shall be developed
solely by Protalix’s employees, for any purpose that is not related in any manner to
the manufacturing, developing, selling and/or commercialization of the Proteins or
the Licensed Products (which Teva IP, for the avoidance of doubt, shall include any
Other IP that may be assigned to Teva pursuant to Section 11.4 above).
	 
	 	11.8.	 	Except as otherwise set forth in this Agreement, Teva and Protalix shall
retain their respective unrestricted rights to make, have made, use and sell all
such data, information, discoveries or inventions that are or may be owned by them,
provided however that Protalix shall not be entitled to sell, pledge (other than in
the ordinary course of business for the receipt of credit-lines) or assign any
portion of the Licensed Information without prior written approval by Teva.
	 
	 	11.9.	 	Each Party hereto undertakes to sign, execute and deliver all documents and
papers that may be required, and perform such other acts as may be reasonably
required in the circumstances, in order to ensure the division of the intellectual
property rights between the Parties in accordance with the terms of this Section 11,
as well as the filing of any and all patents arising hereunder and the registration
of the License granted hereunder.

12. Prosecution and Protection of Intellectual Property

Patent Filing

	 	12.1.	 	Throughout the term of the License granted hereunder,
[***] shall be
obligated, at its own expense, to file, record, prosecute, and maintain all patent
rights with respect to the  [***] in the countries as set forth in Annex 12.1
attached hereto (the “Current Countries”). In addition, throughout the
performance of the Feasibility Program only, [***] shall be obligated to file,
record, prosecute and maintain, all patent rights with respect to the [***] in all
the Major Countries. In addition, [***] shall have the right, at its own expense, to
file, record, prosecute, and maintain all patent rights with respect to the [***],
in all other countries which are not the Current Countries.
	 
	 	12.2.	 	Notwithstanding 12.1 above, as of the provision of Stage 2 Notice by [***],
[***] shall, at [***] expense and as long as this Agreement is in effect, file,
record, prosecute and maintain all patent rights with respect to the [***], in the
Major Countries, and, at its discretion, in the other countries of the world.
	 
	 	12.3.	 	Each Party shall provide the other Party with a prior written notice
regarding filing of each patent application which is filed pursuant to section 12.1
or 12.2, and shall furthermore give reasonable consideration to the comments
received by the other with respect to the filing of such patents. Each Party shall
provide the other with reasonable information relating to the prosecution of such
Party’s IP [***], and the maintenance and other proceedings relating thereto
including, without limitation, by providing copies of substantive communications,
notices, actions, search reports and third party observations submitted to or
received from patent offices. Provision of all such documentation and information
from one Party to the other shall be at no cost to the receiving Party.
	 
	 	12.4.	 	In the event that [***] fails to file, record, prosecute or maintain all
patent rights with respect to the [***] in all the Current Countries or, as
applicable throughout the

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 25 - 

 

	 	 	 	performance of the Feasibility Program, the [***] in any
of the Major Countries, which failure constitutes a breach of its obligations under
Section 12.1 above, then [***] shall be entitled to terminate this Agreement and
to any other remedy provided to it under law.
	 
	 	12.5.	 	If [***] elects not to file, record, prosecute or maintain all patent
rights with respect to the [***] in countries other than the Current Countries or,
as applicable, [***], in any country of the world which is not one of the Major
Countries, [***] shall notify [***]in writing of such election to allow [***], in
its sole discretion, to file and/or continue to prosecute such patent application
and/or maintain such patent in such country at its own cost and expense. In such
event, for as long as [***] continues to prosecute and maintain such patents,
then, in respect of such country, [***] shall not be obligated to pay [***] in such
country protected or to be protected by such patent until such time as [***] out of
pocket expenses incurred in prosecuting and/or maintaining such patents are
recouped. [***] shall notify [***] in writing of [***] election as aforesaid. For
the avoidance of doubt, it is hereby clarified that should [***] assume control
over the prosecution and maintenance of such patents as aforesaid, then at any time
thereafter [***] may, in its sole discretion, cease the prosecution and maintenance
of such patents, upon prior written notice to [***].
	 
	 	12.6.	 	If [***] elects not to file, record, prosecute or maintain all patent
rights with respect to the [***] in any of the Major Countries, [***] shall notify
[***] in writing of such election to allow [***], in its sole discretion, to file,
record and/or continue to prosecute such patent application and/or maintain such
patent in such country. In such event, for as long as [***] continues to file,
record, prosecute and maintain such patents or patent applications and notifies
[***] of same, then, in respect of such country, with respect to the [***] in any
of the Major Countries, [***] shall reimburse [***] for [***] out of its patent
expenses.
	 
	 	12.7.	 	Nothing contained herein shall be deemed to be a warranty by either of the
Parties that they can or will be able to obtain patents on patent applications
included in the Licensed Information or that any such patents will afford adequate
or commercially worthwhile protection.

Patent Enforcement

	 	12.8.	 	In the event that either Party hereto becomes aware of any product that is
made, used, or sold or any action that it believes infringes or misappropriates the
Licensed Information applicable to the Licensed Products or the Teva IP
(collectively, “Product IP”), such Party will promptly advise the other of all the
relevant facts and circumstances known to such first-mentioned Party in connection
with such infringement or misappropriation.
	 
	 	12.9.	 	Prior to the provisions of a Stage 2 Notice, with respect to [***], [***]
shall, at its own expense, enforce the [***], or any part thereof, against
infringement or misappropriation, bring an action against any third party suspected
of infringement or misappropriation of same and control the defense of any
counterclaim or declaratory judgment action (or other action) relating thereto;
[***] will fully cooperate with [***] at [***] expense, with respect to the
investigation and prosecution of such alleged infringement or misappropriation
including the eventual joining of [***] as a party to such action, as may be
required by the law of the particular forum where enforcement is being sought. Any
recovery obtained as a result of such action shall

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 26 - 

 

	 	 	 	be applied first to the
documented costs and expenses actually incurred by [***], and [***] shall retain any
and all remaining amounts recovered.
	 
	 	12.10.	 	As of provision of the Stage 2 Notice, with respect to the [***], [***] shall have
the first right, but not the obligation, to bring an action against any third party
suspected of infringement or misappropriation of same, and to control the defense of
any counterclaim or declaratory judgment action alleging invalidity or
non-infringement (or other action) relating thereto. If
[***] elects to bring such
action against a third party, [***] will fully cooperate with [***], at [***]
expense, with respect to the investigation and prosecution of such alleged
infringement or misappropriation, including the joining of [***] as a party to such
action, as may be required by the law of the particular forum where enforcement is
being sought. Any recovery obtained as a result of such action shall be split, after
the deduction of the documented costs and expenses actually incurred by [***], so
that [***] will be entitled to [***] and [***] shall retain [***] out of the amounts
which constitute compensation for loss of sales. All other amounts shall be retained
by [***].
	 
	 	 	 	As of provision of the Stage 2 Notice [***] may, at its own expense, enforce the [***],
or any part thereof, against infringement or misappropriation, bring an action against
any third party suspected of infringement or misappropriation of same and control the
defense of any counterclaim or declaratory judgment action (or other action) relating
thereto if [***] fails, within sixty (60) days after becoming aware of such
infringement, or receiving notice from [***] of such infringement, to take reasonable
action to investigate such alleged infringement. [***] will fully cooperate with [***],
at [***] expense, with respect to the investigation and prosecution of such alleged
infringement or misappropriation including the joining of [***] as a
party to such action, as may be required by the law of the particular forum where
enforcement is being sought. Any recovery obtained as a result of such action taken by
[***] shall be retained by [***] in full.
	 
	 	12.11.     	 	Each Party shall execute all necessary and proper documents, take such actions as
shall be appropriate to allow the other Party to institute and litigate such
infringement actions referred to in this Section 12, and shall otherwise cooperate
in the institution and litigation of such actions (including, without limitation,
consenting to being named as a party thereto). Each Party, in litigating any such
infringement actions, shall keep the other Party reasonably informed as to the
status of such actions.

Patent Infringement

	 	12.12.     	 	As of the provision of Stage 2 Notice by Teva, in the event that either Teva or
Protalix, or both of them, are sued by a third party alleging that the
commercialization of the Licensed Products infringes upon any intellectual property
rights of such third party the Party being so sued shall immediately give the other
Party notice of same.
	 
	 	 	 	Teva shall have the right to defend against such action, on behalf of both Parties, as
aforesaid within twenty (20) business days from the date the relevant suit becomes known
to Teva, and any expenses or costs incurred by Teva in connection with such action(s),
and any costs or amounts awarded to the counterparties in such action(s) shall be fully
borne by Teva and any recovery in such action shall be retained by Teva in full. In the
event that Teva does not exercise its right to defend in a certain country, then
Protalix shall be entitled to defend against such claim at its own cost and

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 27 - 

 

	 	 	 	expense in
such country and any recovery in such action shall be retained by Protalix
in full. In addition, in such event that Protalix defends against such claim, Protalix
shall have the right to terminate the License provided hereunder in respect of such
country (in which the defense is taken) only with respect to the certain Licensed
Product as to which the claim relates.

General

	 	12.13.	 	A Party shall be deemed to have met its obligation to file, record, prosecute,
maintain, enforce and defend patents in accordance with Section 12 above if its
decision is commercially reasonable solely in view of the foreseeable impact of any
action or inaction on the development or commercialization of Licensed Products.
For the sake of clarity, such obligations shall apply to the Platform Patents only
in respect of actions that may be taken in the Current Countries after the
Effective Date.
	 
	 	12.14.	 	Protalix and Teva will reasonably co-operate in the defense of any claims brought
against the other Party pursuant to this Agreement and shall voluntarily join any
such litigation if so required by law. Protalix and Teva will execute all documents
reasonably necessary for the relevant Party to defend against such action, and shall
provide documents and help with making contact with witnesses that are or were their
employees, consultants or otherwise connected to them, whose testimony — in the
judgment of the attorneys handling the law suit (or Teva’s or Protalix’s counsel in
the event the proceedings will be brought only on the name of one Party) — is
necessary to allow such litigation to go forward.
	 
	 	12.15.	 	In no event shall either Party enter into any settlement, consent order, consent
judgment or any voluntary disposition of such action that would adversely affect the
rights of the other without the prior written consent of such other Party, which
consent shall not be unreasonably withheld.

13. New Breakthrough Technology

	 	13.1.	 	Should Protalix develop on its own or receive a license to Breakthrough
Technology, Protalix shall notify Teva thereof as soon as practicable, and provide
Teva with all information related thereto, and enter into discussions with Teva, in
good faith, with a view towards granting Teva or procuring the grant to Teva of an
exclusive worldwide license to utilize such Breakthrough Technology as it relates
solely to the Proteins and/or the Licensed Products, but shall not be bound to such
discussions if Teva did not initiate negotiation with Protalix in such respect for a
period exceeding [***] of its provision of such information to Teva as
provided above.
	 
	 	13.2.	 	The license to the Breakthrough Technology shall be granted by Protalix to
Teva in return for [***], as shall be
discussed and agreed in good faith between the Parties.

For the purposes hereof, the term “Breakthrough Technology” means any [***].

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 28 - 

 

14. Right of First Look – GCD Product

	 	14.1.	 	Protalix hereby grants Teva and Teva hereby accepts from Protalix a right of
first look (the “ROFL”) at Protalix’s proprietary product based on
glucocerebrosidase which is currently under development, for the treatment of
Gauchers Disease and for other clinical indications (the “GCD Product”), to enable
Teva to evaluate its interest in obtaining an exclusive, worldwide license to
develop, commercialize, manufacture, market, distribute and sell the GCD Product for
all indications, including without limitation Gauchers Disease (the “GCD License”).
	 
	 	14.2.	 	The period of time during which the ROFL shall be valid, is referred to
hereunder as the “Evaluation Period”. The Evaluation Period shall start as of the
Effective Date and shall automatically terminate, on a per country basis, upon: (x)
Protalix exclusively licensing the GCD Product (with respect to all indications) to
one or more third parties in all of the Major Countries, or (y) the commercial
launch of the GCD Product by Protalix in all of the Major Countries, provided
Protalix fully complied with the provisions of this section 14. If licenses to third
parties in respect of the Major Countries subsequently terminates, the ROFL to Teva
shall be reinstated pursuant to the terms of this Section 14.
	 
	 	14.3.	 	Throughout the Evaluation Period, Protalix shall submit to Teva within thirty
(30) days after the end of each calendar quarter, a written report briefly
describing all updates in its research and development activities in relation to the
GCD Product and the results thereof. Notwithstanding the above, if a material event
has occurred relating to the development of the GCD Product then Protalix shall so
notify Teva promptly.
	 
	 	14.4.	 	At any time or times during the Evaluation Period Teva may notify Protalix in
writing, that it wishes to negotiate the terms and conditions of the GCD License
(the “Notice”). In such event, Protalix shall be bound to an exclusive negotiation
period of [***] as of the date of the Notice (the “Negotiation Period’)
during which time the Parties shall act in good faith and endeavor to finalize the
terms and conditions of a license agreement to govern the grant to Teva of the GCD
License (the “GCD License Agreement”). If the Parties fail to execute GCD License
Agreement by the expiry of the Negotiation Period, the Parties shall endeavor to
finalize the GCD License Agreement as soon as possible thereafter, without Protalix
being barred, however, from negotiating with any third party. The exclusive [***] Negotiation Period shall not occur more than [***]. For the
avoidance of doubt, under no circumstances shall Protalix be barred from launching
or commercially selling the GCD Product by itself and/or through an Affiliate, and
for as long as Protalix intends to do so in any Major Country (as evidenced by a
board resolution), Protalix shall not be required to conduct negotiations with Teva
following receipt of any Notice pursuant to this Section 14.4, in respect to such
Major Country. Protalix shall provide Teva with a copy of such board resolution, at
its request.
	 
	 	14.5.	 	During the Negotiation Period: (i) Teva shall have the right to evaluate the
GCD Product to determine its interest in receiving the GCD License, and to receive
all data and information related to the GCD Product generated or
received by Protalix prior to the commencement of or during the Negotiation Period,
excluding only information regarding commercial terms related to previous
negotiations with third parties; (ii) Protalix shall not grant any third party any
rights to or in respect of the GCD Product

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 29 - 

 

	 	 	 	which may interfere with the grant of the GCD License to Teva or provide any third party with any information relating to
the GCD Product.

	 	14.6.	 	Without derogating from the above, should a third party show interest in
acquiring a license for the GCD Product for any indication from Protalix at any time
during the Evaluation Period except during a Negotiation Period, and Protalix will
decide to enter into negotiations with such third party (the “Third Party
Negotiation Period”), Protalix shall so notify Teva immediately in writing, and will
disclose to Teva all updated information regarding the GCD Product available during
and throughout the Third Party Negotiation Period such that Teva may be able to
negotiate in parallel with full and complete updated GCD Product information
disclosed. For the avoidance of doubt, Protalix shall not be entitled to accept an
offer from any third party in connection with the licensing of GCD Product for any
indication unless Protalix has first complied with the terms of this Section 14.
	 
	 	14.7.	 	In the event that, at the time Teva exercises its right to enter into the
Negotiation Period, Protalix is already in a Third Party Negotiation Period, then,
notwithstanding the exclusivity provision set forth above, Protalix may continue
negotiating with such third party ONLY, but not with any other third party or parties
(for so long as the Negotiation Period is in effect).
	 
	 	14.8.	 	It is hereby agreed that in the event that the Parties will agree upon a
definitive agreement with respect to the GCD License, such agreement shall include a
provision setting out a mechanism whereby Protalix will not compete with Teva through
a second generation GCD Product.

14A Services by Teva regarding the [***]

	 	14A.1	 	Teva will provide Protalix with  [***]
with respect to the [***] for the performance of Phase III clinical trials, as set
forth in Section 14A.3 below, all in accordance with applicable regulatory requirements
(collectively, the “[***] Services”).
	 
	 	14A.2	 	The price of the [***] Services shall be [***] in the aggregate, and such price shall
be invoiced on a [***] basis, and paid within thirty (30) days of the end of the [***]
during which Protalix receives an invoice from Teva, subject to performance of such [***]
Services. Any material increase in the cost of the [***] Services stated above will be
discussed and negotiated in good faith between the management of both Parties.
	 
	 	14A.3	 	The [***] Services shall entail the provision of [***] which assumes that [***] will be used, and assumes a target fill volume of approximately
[***]. In the event that more than [***] shall be required by Protalix, the Parties hereto shall
mutually agree on an adjustment to the [***] to be provided hereunder, and the price per [***]
shall be calculated [***].

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 30 - 

 

Teva shall compile the requisite batch production documentation or a batch master
file and provide the same to Protalix.

14A.4 The comprehensive timeline and the detailed description of the [***] Services shall be
attached hereto as Annex 14A.4 within thirty (30) days of the Effective Date.

14A.5 Teva will provide Protalix with any regulatory documentation in its possession in
respect of the [***] Services, as may be required pursuant to an audit by regulatory
authorities and as may required for the submission of a CMC file (for example Media Fill,
Closure Integrity test, etc.). Protalix’s QA representatives and/or regulatory QP persons
shall have the right to visit and audit Teva’s [***] site for the sole purpose of
regulatory audit at times to be coordinated in advance between the Parties, but only to the
extent required by the relevant regulatory authorities for the conduct of the Phase III
clinical trials.

14A.6 Following the completion of the performance of the [***] Services, Protalix shall have
the option to request that Teva continue the performance of the [***] with respect to the [***] on a
commercial basis (the “Commercial [***] Services”), and in the event that Protalix shall
request that Teva perform the Commercial [***] Services, the terms of same (including the
pricing of batch production) shall be negotiated in good faith between the Parties, to
reflect a competitive market price at the relevant time. For the avoidance of doubt, it is
clarified that Teva shall only be required to provide the Commercial [***] Services in the
event that both Parties hereto agree on the terms of the provision of same.

14A.7 At any time, Protalix may request that Teva transfer to Protalix a technology
transfer file, and in such event Teva shall promptly provide the same to Protalix. The
reasonable costs of such transfer, as demonstrated by Teva, shall be reimbursed to Teva by
Protalix within thirty (30) days of the receipt from Teva of an invoice in respect of same,
along with supporting documentation.

15. Term and Termination 

	 	15.1.	 	This Agreement shall be effective from the date of receipt of all necessary
corporate approvals of Teva required in respect of this Agreement (the “Effective
Date”) and shall continue in full force and effect until terminated in accordance
with the terms hereof. For the avoidance of doubt, Protalix hereby acknowledges that
the approval of the Board of Directors of Teva is required,
and that in the event that such approval is not received, this Agreement shall have
no force or effect whatsoever.
	 
	 	15.2.	 	Teva shall have the right to terminate this Agreement for any reason with
respect to both or any specific Protein (the “Terminated Protein”), by providing
Protalix with

	 		
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 31 - 

 

	 	 	 	thirty (30) days prior written notice of such decision. In the event
that only one Protein is terminated, this Agreement shall remain in full force and
effect with respect to the remaining Protein which is not a Terminated Protein. No
compensation from Teva to Protalix shall be due as a result of such termination.
	 
	 	15.3.	 	Upon the termination of this Agreement by Teva pursuant to Section 15.2
above, with respect to any specific Protein, the following shall apply:

	 	15.3.1.	 	the License granted to Teva by Protalix, with regard to
Licensed Products based on such Protein shall be terminated;
	 
	 	15.3.2.	 	Teva shall provide Protalix with a report summarizing its
development activities and the results up to termination.

	 	15.4.	 	Without derogating from any other remedies that either Party hereto may have
under the terms of this Agreement or at law, each Party hereto shall have the right
to terminate this Agreement forthwith upon the occurrence of any of the following:

	 	(i)	 	the commission of a material breach by the other
Party hereto of its obligations hereunder, and such other
Party’s failure to remedy such breach within sixty (60) days
after being requested in writing to do so by the non-breaching
Party; or
	 
	 	(ii)	 	the other Party’s liquidation, whether voluntarily
or otherwise, or its entering into any arrangement with its
creditors.

	 	15.5.	 	Notwithstanding anything to the contrary in this Agreement, to the extent
that a Party (the “Respondent”) reasonably and in good faith disagrees with any
assertion by the other Party (the “Claimant”) that there has been a material breach
of this Agreement by Respondent, and Respondent provides written notice to Claimant
of its disagreement and the basis for its belief (a “Rebuttal Notice”) within
fifteen (15) days after Respondent receives notice from Claimant of a breach, this
Agreement will remain in effect and any termination of this Agreement further to
Section 15.4(i) hereunder will be suspended pending resolution of such disagreement
between the Parties as provided in Section 23.18 below. The Parties will attempt to
resolve such disagreement as expeditiously as possible and Respondent will continue
to comply with the provisions of this Agreement, to the extent that they are not the
subject of the disagreement between the Parties. For the avoidance of doubt, it is
clarified that nothing in this Section 15.5 shall derogate from Teva’s right of
termination pursuant to Section 15.2, at any time and for any reason.
	 
	 	15.6.	 	Upon termination of this agreement for whatever reason, each Party shall
immediately return to the other party all materials, reports, updates,
documentation, written instructions, notes, memoranda, discs or records or other
documentation or physical matter of whatsoever nature or description provided by
the other Party, except in the event that such material is owned by such Party
pursuant to the terms of this Agreement, and provided that each Party shall be
allowed to retain one (1) copy for archival purposes.
	 
	 	15.7.	 	In the event that following termination of this Agreement for convenience or
breach by Teva, Protalix shall request the license to utilize the Teva IP for the
sole purpose of the further development, manufacturing, commercialization, marketing
and sale of a Licensed Product, then Teva will enter into discussions with Protalix,
in good faith, with a view towards granting Protalix such license, but shall not be
bound to grant

 - 32 - 

 

	 	 	 	such license. Such license to the Teva IP shall be granted by Teva in
return for reasonable consideration by industry standards, as shall be discussed and
agreed in good faith between the Parties. For the avoidance of doubt, following
termination of this Agreement pursuant to Section 15.4 due to a breach hereof by
Protalix, Teva shall not be required to enter into discussions with Protalix
regarding any request of Protalix to grant any license to the Teva IP.

	 	15.8.	 	Upon termination hereof for any reason, each Party shall be entitled to
collect any debt then owed to it by the other Party.
	 
	 	15.9.	 	Save as explicitly stipulated otherwise in any Agreement, any provision, that
by its nature, is intended to survive termination, shall survive the termination or
expiration of this Agreement.

16. Representations

	 	16.1.	 	Each Party hereby represents to the other Party that:

	 	16.1.1.	 	it has the full power and authority to enter into this
Agreement and to perform its obligations hereunder, and that subject to
Section 15.1 with respect to Teva, that all corporate approvals have been
obtained.
	 
	 	16.1.2.	 	entering this Agreement shall not constitute a breach of any
agreement, contract, understanding and/or obligation, including such
Party’s documents of incorporation, that it is currently bound by, and as
long as this Agreement is in effect and without derogating from the rights
to terminate the Agreement pursuant to Section 15 above, such Party shall
not undertake any obligations which conflict with its obligations under
this Agreement.

	 	16.2.	 	In addition, Protalix hereby represents and warrants that:

	 	16.2.1.	 	it is the sole and exclusive owner of the existing Platform
Patents, and the existing Platform IP, and that all right, title and
interest therein and thereto vest in Protalix, and that no third party,
other than the CSO to the extent applicable, has any rights whatsoever
(including the right to receive royalties or any other compensation) in
respect of the existing Platform Patents, and the existing Platform IP;
	 
	 	16.2.2.	 	No third party, has or shall have any rights whatsoever
(including the right to receive royalties or any other
compensation) in respect of any results of the Feasibility Program
and Stage 2 activities to be conducted by or for Protalix, except
as might be agreed pursuant to Section 4.16;
	 
	 	16.2.3.	 	To the best of its knowledge, the performance of Protalix’s
obligations under this Agreement, and the exploitation of the Platform IP
do not infringe upon any third party intellectual property rights
currently existing;
	 
	 	16.2.4.	 	it has the right and authority, as the proprietor of the
Platform IP, to grant the License;
	 
	 	16.2.5.	 	it has no knowledge of any legal suit or proceeding by a
third party against Protalix contesting the ownership or validity of the
Licensed

 - 33 - 

 

	 	    	 	Information or any part thereof or contesting the possible
exploitation of the License granted hereunder (including as it relates to
the commercialization of the Licensed Products) as infringing upon any
third party intellectual property rights;

	 	16.2.6.	 	it shall not, during the term of this Agreement, perform any
work or other activities on or in respect of the Proteins, except in the
course of the collaboration hereunder;
	 
	 	16.2.7.	 	it has the financial capacity to carry out all its
obligations hereunder, including, the performance of the Feasibility
Programs in accordance with the timelines set forth therein;
	 
	 	16.2.8.	 	other than in respect of the Platform IP, it has not received
and hereby undertakes that it shall not receive any funding from the CSO
in respect of the Licensed Information, the Feasibility Programs or the
performance thereof, or the performance of any other of its obligations
under this Agreement; and in respect of the Platform IP, Protalix shall
bear any and all amounts due to the CSO;
	 
	 	16.2.9.	 	it has the necessary experience and expertise to perform each
of the Feasibility Programs, and its share of the Development Plan during
Stage 2;
	 
	 	16.2.10.	 	Protalix does not have any Affiliates; and that
	 
	 	16.2.11.	 	in carrying out its undertakings and responsibilities
pursuant to this Agreement, Protalix shall comply with all applicable laws
and regulations, licenses, permits, approvals and procedures.

16.3. In addition, Teva hereby represents and warrants that in carrying out its
undertakings and responsibilities pursuant to this Agreement, Teva shall comply, and
shall require that its Affiliates, Sub-licensees and Further Sub-licensees comply,
with all applicable laws and regulations, licenses, permits, approvals and
procedures.

16.4. Without derogating from any of the remedies available to either Party
hereunder or under applicable law, if either Party shall become aware of the
inaccuracy of any of the above representations, such Party shall immediately
notify the other Party of such in writing.

16.5. Both Teva and Protalix represent that they shall perform their obligations
hereunder diligently, expeditiously and to the best of their abilities.

16.6. Except as otherwise expressly provided in this Agreement, no Party makes any
warranty with respect to any technology, patents, goods, services, rights or other
subject matter of this Agreement and each Party hereby disclaims warranties of
merchantability, fitness for a particular purpose and non-infringement with respect
to any and all of the foregoing. Without derogating from the generality of the
foregoing, nothing contained in this Agreement is a warranty or representation by
Protalix or Teva that any efforts to be exerted by Protalix or Teva in connection
with this Agreement including without limitation any development activities to be
performed by it hereunder, or any part thereof, will actually achieve their aims or
succeed, and the Parties make no warranties whatsoever as to any results to be
achieved in consequence of the carrying out of any such efforts or activities; and
that any patents will be issued with respect to

 - 34 - 

 

the patent applications that are or
may constitute part of the list of Platform Patents, or that patents obtained on any
of the said patent applications are or will be valid or will afford proper
protection or that the Licensed Information will be commercially exploitable or of
any other value.

17. Indemnification 

17.1. Teva shall indemnify, defend, and hold harmless each of Protalix and its
directors, officers, employees, and agents and its respective successors, heirs and
assigns (the “Protalix Indemnitees”), from and against any liability, damage, loss,
or expense (including reasonable attorney’s fees and expenses of litigation)
incurred by or imposed upon any of Protalix Indemnitees in connection with any
claims, suits, actions, demands or judgments (“Claims”) arising pursuant to a breach
of a representation or warranty of Teva hereunder and/or concerning the use of any
Licensed Information by Teva, or any of its Affiliates or Sub-licensees or Further
Sub-licensees, or concerning any Licensed Product that is developed, tested, made,
used, or sold pursuant to any right or license granted by Protalix to Teva under
this Agreement (except in cases where, and to the extent that, such Claims are
finally proven to result from the gross negligence and/or willful misconduct on the
part of any of the Protalix Indemnitees and/ or any misrepresentation by Protalix
hereunder).

17.2. Teva’s undertakings under Section 17.1 above shall be subject to: (a) receipt
of prompt written notice of any Claim by the Protalix Indemnitee (provided, however,
that the failure to give such notice shall not affect Teva’s indemnification
undertakings provided hereunder except to the extent Teva shall have been actually
prejudiced as a result of such failure), (b) the cooperation of the Protalix
Indemnitee(s) regarding the response to and the defense of any such Claim, and (c)
Teva’s right, by written notice to the Protalix Indemnitees, to assume the defense
of the Claim or represent the interests of the Protalix Indemnitees in respect of
such Claim, that shall include the right to select and direct legal counsel and
other consultants to
appear in proceedings on behalf of the Protalix Indemnitees and to propose,
accept or reject offers of settlement, all at its sole cost; provided
however, that no such settlement shall be made without the written
consent of the Protalix Indemnitees, such consent not to be unreasonably
withheld or delayed. Nothing herein shall prevent the Protalix Indemnitees from
retaining their own counsel and participating in their own defense at their own
cost and expense.

17.3. Protalix shall indemnify, defend, and hold harmless each of Teva and its
directors, officers, employees, and agents and its respective successors, heirs and
assigns (the “Teva Indemnitees”), from and against any liability, damage, loss, or
expense (including reasonable attorney’s fees and expenses of litigation) incurred
by or imposed upon any of Teva Indemnitees in connection with any claims, suits,
actions, demands or judgments (“Claims”) arising pursuant to a breach of a
representation or warranty of Protalix hereunder and/or concerning the research,
development or manufacturing activities of Protalix hereunder (except in cases
where, and to the extent that, such Claims are finally proven to

 - 35 - 

 

result from the
gross negligence and/or willful misconduct on the part of any of the Teva
Indemnitees and/ or any misrepresentation by Teva hereunder).

17.4. Protalix’s undertakings under Section 17.3 above shall be subject to: (a)
receipt of prompt written notice of any Claim by the Teva Indemnitee (provided,
however, that the failure to give such notice shall not affect Protalix’s
indemnification undertakings provided hereunder except to the extent Protalix shall
have been actually prejudiced as a result of such failure), (b) the cooperation of
the Teva Indemnitee(s) regarding the response to and the defense of any such Claim,
and (c) Protalix’s right, by written notice to the Teva Indemnitees, to assume the
defense of the Claim or represent the interests of the Teva Indemnitees in respect
of such Claim, that shall include the right to select and direct legal counsel and
other consultants to appear in proceedings on behalf of the Teva Indemnitees and to
propose, accept or reject offers of settlement, all at its sole cost;
provided however, that no such settlement shall be made without the
written consent of the Teva Indemnitees, such consent not to be unreasonably
withheld or delayed. Nothing herein shall prevent the Teva Indemnitees from
retaining their own counsel and participating in their own defense at their own cost
and expense.

18. Insurance

Each Party hereto shall maintain, for the term of this Agreement and thereafter,
insurance sufficient to cover its obligations under this Agreement and under law as it
customarily maintains for similar activities in the regular course of its business.
Protalix’s insurance obligations with respect to the manufacturing of the API will be
included in the Supply Agreement. Teva may fulfill its obligation hereunder to obtain
insurance by the maintenance of appropriate self insurance regardless of the nature or
title thereof.

19. Limitation of Liability 

IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER OR ANY OF
ITS AFFILIATES FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY
DAMAGES (INCLUDING, WITHOUT LIMITATION, LOST PROFITS, BUSINESS OR GOODWILL) SUFFERED OR
INCURRED BY SUCH OTHER PARTY OR ITS AFFILIATES, WHETHER BASED UPON A CLAIM OR ACTION OF
CONTRACT, WARRANTY, NEGLIGENCE OR TORT, OR OTHERWISE, ARISING OUT OF THIS AGREEMENT.

20. Confidentiality 

20.1. Other than as expressly set forth herein, Teva and Protalix undertake to
treat and to maintain and to ensure that their Representatives (as defined below)
shall treat and maintain, in strict confidence and secrecy any information disclosed
by either Party under this Agreement, whether disclosed in oral or visual form or in
writing and shall keep in confidence the existence and contents of this Agreement
(the “Confidential Information”) and shall not disclose, publish, or disseminate in
any manner, any Confidential Information including, without limitation, any aspect
thereof which may have been disclosed prior to the signature hereof to a third party
other than those of its Representatives with a need to know same for the purpose of
performing its obligations under this Agreement (the “Purpose”).

 - 36 - 

 

In addition, each
Party shall undertake to treat and maintain (and to ensure that its Representatives
treat and maintain) in strict confidence and secrecy and to prevent any unauthorized
use, disclosure, publication, or dissemination of the Confidential Information,
except for the Purpose. Each Party agrees to be responsible for any use or
disclosure of Confidential Information of any of its said Representatives.

20.2. Each Party shall:

	 	20.2.1.	 	safeguard and keep secret all Confidential Information, and
will not directly or indirectly disclose to any third party the
Confidential Information without written permission of the other.
	 
	 	20.2.2.	 	in performing its duties and obligations hereunder, use at
least the same degree of care as it does with respect to its own
confidential information of like importance but, in any event, at least
reasonable care.

20.3. The undertakings and obligations under Sections 20.1 and 20.2 above shall not
apply to any part of the Confidential Information which:

	 	20.3.1.	 	was known to the recipient of the Confidential Information
(“Recipient”) prior to disclosure by the disclosing Party (“Discloser”);
	 
	 	20.3.2.	 	was generally available to the public prior to disclosure to
the Recipient;
	 
	 	20.3.3.	 	is disclosed to Recipient by a third party who is not bound
by any confidentiality obligation, having a legal right to make such
disclosure;
	 
	 	20.3.4.	 	has become through no act or failure to act on the part of
the Recipient public information or generally available to the public;
	 
	 	20.3.5.	 	was independently developed by Recipient without reference to
or reliance upon the Confidential Information;
	 
	 	20.3.6.	 	is required to be disclosed by Recipient by law, by court
order, or governmental regulation (including securities laws and/or
exchange regulations), provided that the Recipient gives Discloser
reasonable notice prior to any such disclosure and cooperates (at
Discloser’s expense) with Discloser to assist Discloser in obtaining a
protective order or other suitable protection from disclosure (if
available) with respect to such Confidential Information.

20.4. Teva and Protalix acknowledge that the respective Confidential Information is
of special and unique significance to each of them and that any unauthorized
disclosure or use of the Confidential Information could cause irreparable harm and
significant injury to the Discloser that may be difficult to ascertain. Accordingly,
any breach of this Agreement may entitle the aggrieved Party in addition to any
other right or remedy that it may have available to it by law or in equity, to
remedies of injunction, performance and other relief, including recourse in a court
of law.

20.5. Each Party agrees to inform the other Party of any breach or threatened
breach of the provisions hereof by its Representatives.

 - 37 - 

 

20.6. The provisions relating to confidentiality in this Section 20 shall remain in
effect during the term of this Agreement and for a period of three (3) years after
its termination.

20.7. “Representatives” shall mean employees, officers, agents, subcontractors,
consultants, and/or any other person or entity acting on either Party’s behalf,
individually or collectively and which shall be exposed to Confidential Information.

20.8. Notwithstanding the foregoing, each Party may disclose the terms of this
Agreement to the extent required, in the reasonable opinion of such Party’s legal
counsel, to comply with applicable laws, as well as to Sub-licensees and prospective
and current investors, pursuant to appropriate non-disclosure arrangements, provided
however that prior to any disclosure, the disclosing Party shall consult with the
non-disclosing Party, and the non-disclosing Party shall have the right to delete
business sensitive issues.

21. Publication

Neither Party shall issue any press release, make any public statement or advertise any
information pertaining to this Agreement, or to the collaboration hereunder, without the
prior written approval of the other, except as required by applicable
law.

Without
derogating from the foregoing, disclosure required under applicable law and regulations
shall not be subject to the written consent of the other Party, however the disclosing
party shall give the other sufficient notice, as far as practicable under law, of such
required disclosure as to enable the non-disclosing Party time to object to such
disclosure.

22. Independent Parties

22.1. This Agreement shall not make either Party the agent or legal representative
of the other Party. Neither Party is granted any right or authority to assume or to
create any obligation or responsibility, expressed or implied, on behalf of or in
the name of the other Party, with regard to any manner or thing whatsoever, unless
otherwise specifically agreed upon in writing.

22.2. Protalix hereby agrees that its employees, officers, agents, subcontractors,
consultants, and/or any other person or entity acting on Protalix behalf,
individually or collectively, shall be the sole responsibility of Protalix and shall
not be considered at any time as Teva employees and shall not have any claims
against Teva whatsoever.

23. Miscellaneous

23.1. The headings in this Agreement are intended solely for convenience or
reference and shall be given no effect in the interpretation of this Agreement.

23.2. All amounts required to be paid pursuant to this Agreement are final and
inclusive of all taxes and/or duties, of whatsoever nature, except for VAT, which
are now or may hereafter be imposed with regard to this Agreement.

23.3. All payments to be made hereunder shall be made by the due date for payment
as provided herein, in US Dollars or in New Israeli Shekels (“NIS”), as converted
from US Dollars as per the representative rate of the US Dollar against the NIS

 - 38 - 

 

 last published by the Bank of Israel prior to the actual date of payment.

23.4. If applicable laws require that taxes be withheld from any amounts due to
Protalix under this Agreement, Teva shall (a) deduct these taxes from the remittable
amount, (b) pay the taxes to the proper taxing authority, and (c) deliver to
Protalix a statement including the amount of tax withheld and justification
therefor, and such other information as may be necessary for tax credit purposes.

23.5. Teva shall be entitled to set-off from any amounts due to Protalix hereunder,
any amounts not exceeding the amounts of any damage caused to Teva, including
without limitation, as a result of Protalix’s breach hereunder.

23.6. Teva shall be entitled to perform any and all of its obligations arising
under the terms of this Agreement and to exploit any and all of its rights arising
under the terms of this Agreement either directly or through its Affiliates,
provided that Teva remains liable to the performance of all of its obligations
hereunder.

23.7. Without derogating from Teva’s right to grant Sublicenses hereunder, neither
Party may assign its rights or its obligations hereunder, in whole or in part,
except with the prior written consent of the other Party. Notwithstanding the
foregoing, (i) provided that Teva remains liable to the performance of all of its
obligations hereunder, Teva may assign its rights and obligations hereunder to an
Affiliate thereof, and such assignment may be made by Teva, at Teva’s sole
discretion, either in respect of the entire Agreement, or with respect to the rights
and obligations related to any part of this Agreement; and (ii) Protalix may assign
its rights and obligations hereunder to any party
acquiring all of the business to which this Agreement pertains, other than to a
Teva Competitor.

23.8. Should any part or provision of this Agreement be held unenforceable or in
conflict with the applicable laws or regulations of any applicable jurisdiction, the
invalid or unenforceable part or provision shall, provided that it does not go the
essence of this Agreement, be replaced with a revision which accomplishes, to the
extent possible, the original commercial purpose of such part or provision in a
valid and enforceable manner, and the balance of this Agreement shall remain in full
force and effect and binding upon the Parties.

23.9. This Agreement and the annexes attached hereto, constitute the entire
agreement between the Parties with respect to its subject matter and supersede all
prior agreements, arrangements, dealings or writings between the Parties, including
without limitation, the Outlines of Teva — Protalix Co-Operation executed between
the Parties on March 19, 2006. This Agreement may not be varied except in writing
signed by the Parties’ authorized representatives.

	 	23.10.	 	Defined terms used in this Agreement and in the annexes shall have the meanings
ascribed thereto herein and therein. References to Section numbers in this Agreement
and in the annexes are to sections of this Agreement. References to Paragraphs in
the annexes are to paragraphs in the respective annex in which the reference is made
or in other annexes, if so specified.
	 
	 	23.11.	 	No waiver of a breach or default hereunder shall be considered valid unless in
writing and signed by the Party giving such waiver and no such waiver shall be
deemed a waiver of any subsequent breach or default of the same or similar nature.

 - 39 - 

 

	 	23.12.	 	VAT will be added, where applicable, to all payments to be made hereunder and
shall be paid against proper invoices.
	 
	 	23.13.	 	Each Party agrees to execute, acknowledge and deliver such further documents and
instruments and do any other acts, from time to time, as may be reasonably
necessary, to effectuate the purposes of this Agreement.
	 
	 	23.14.	 	None of the provisions of this Agreement shall be enforceable by, any person who
is not a party to this Agreement.
	 
	 	23.15.	 	The remedies afforded to any of the Parties hereto, whether hereunder, or under
applicable law or otherwise, shall be cumulative in nature and not alternative.
	 
	 	23.16.	 	Any notice, declaration or other communication required or authorized to be given
by any Party under this Agreement to any other Party shall be in writing and shall
be personally delivered, sent by facsimile transmission (with a copy by ordinary
mail in either case) or dispatched by courier addressed to the other Party at the
address stated below or such other address as shall be specified by the Parties
hereto by notice in accordance with the provisions of this Section. Any notice shall
operate and be deemed to have been served, if personally delivered, sent by fax or
by courier on the next following day.
	 
	 	 	 	Teva’s and Protalix’s addresses for the purposes of this Agreement shall be as
follows

If to Teva:

Teva Pharmaceutical Industries Ltd.

Attention: Dr. Ram Petter

5 Basel Street, Petah Tiqva 49131

Israel

Telephone: 972-3-9267683

Facsimile: 972-3-9267309

With a copy (that will not constitute notice) to:

Teva Pharmaceutical Industries Ltd.

Attention: General Counsel, Legal Department

5 Basel Street, Petah Tiqva 49131

Israel

Telephone: 972-3-926-7297

Facsimile: 972-3-926-7429

If to Protalix Bio-Pharmaceuticals Ltd.

Protalix Bio-Pharmaceuticals Ltd.

2 Snunit St., Science Park, P.O. Box 455, Carmiel 20100

Israel

Attention: C.E.O.

Telephone: 972-4-9889488

Facsimile: 972-4-9889489

 - 40 - 

 

	 	23.17.	 	Any payment not received when due pursuant hereto shall bear interest from the due
date until the date of actual payment at the rate of [***] (or such other percentage, if lower, as shall not exceed the maximum rate permitted by
law).
	 
	 	23.18.	 	This Agreement shall be governed and interpreted according to the laws of the
State of Israel. Any dispute arising from this Agreement shall be resolved
exclusively by the competent Courts of Tel Aviv-Jaffa, Israel, and by no other court
or jurisdiction.
	 
	 	23.19.	 	This Agreement may be executed in any number of counterparts (including
counterparts transmitted by fax), each of which shall be deemed to be an original,
but all of which taken together shall be deemed to constitute one and the same
instrument.

IN WITNESS WHEREOF, each Party has caused this Agreement to be executed by its duly
authorized representative:

	 	 	 	 	 	 	 	 	 
	TEVA PHARMACEUTICAL INDUSTRIES LTD.
	 	 	 	Protalix Bio-Pharmaceuticals Ltd.

	 
	 	 	 	 	 	 	 	 
	signature:

	 	 /s/ Amir Elstein
	 	 
	 	signature:
	 	 /s/ David Aviezer
	 

	 	 
	 	 	 	 	 	 
	 	 
	name:

	 	      Amir Elstein
	 	 	 	name:
	 	 David Aviezer
	 

	 	 
	 	 	 	 	 	 
	 	 
	designation:

	 	 Group VP, Global Specialty Pharmaceutical
Products
	 	 	 	designation:
	 	           CEO
	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	signature:

	 	 /s/ Keren Siemon
	 	 	 	signature:	 	 
	 

	 	 
	 	 	 	 	 	 
	 	 
	name:

	 	      Keren Siemon
	 	 	 	name:	 	 
	 

	 	 
	 	 	 	 	 	 
	 	 
	designation:

	 	Sr. Director BD and Finance, Global
	 	 	 	designation:	 	 
	 

	 	Specialty	 	 	 	 	 	 
	 

	 	Pharmaceutical Products	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	                        Date: 14 September 2006
	 

	 	                        Date: 14 September 2006
	 	 	 	 	 	 

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 41 - 

 

Annex 1.2.1

List of Additional Patents

[***]

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 42 - 

 

Annex 1.2.42

Platform Patents

[***]

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 43 - 

 

Annex 1.2.44

Proteins

[***]

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 44 - 

 

Annex
3.1.1

Feasibility Program

 - 45 - 

 

Annex 3.1.1A

Outline of the Feasibility Program

[***]

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 46 - 

 

Annex 4.4

Outline of the activities of the Parties under the Development Plan

[***]

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 47 - 

 

Annex 4.17

Key elements of the Supply Agreement

 - 48 - 

 

Annex 8.2

[***]

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 49 - 

 

Annex 12.1 

Current Countries

[***]

 

* The list above is subject to further review by Teva

 

			
	[***]	 	Portions of this exhibit were omitted and filed separately
with the Secretary of the Securities and Exchange Commission pursuant
to the Registrant’s application requesting confidential
treatment under Rule 24b-2 of the Exchange Act.

 - 50 - 

 

Annex 14A.4

Timeline and detailed Description of the GCD Services

 - 51 -EX-10.1 FORM OF ESCROW AGREEMENT

 

EXHIBIT 10.1

FORM OF ESCROW AGREEMENT

     THIS ESCROW AGREEMENT (the “Agreement”) is made and entered into as of the [___] day
of [                    ], 2007, by and between REITPlus, Inc., a Maryland corporation (the
“Company”), AmREIT Securities Company (the “Dealer Manager”) and Wells Fargo Bank,
N.A., as escrow agent (the “Escrow Agent”).

     WHEREAS, the Company proposes to offer for sale, on a continuing basis (the
“Offering”) up to $550,000,000 in shares of the Company’s common stock, par value $0.01 per
share (the “Shares”) pursuant to the terms of the prospectus contained in the registration
statement on Form S-11, as amended,  initially filed with the Securities and Exchange Commission under the
Securities Act of 1933, as amended on May 31, 2007 (the
“Prospectus”);

     WHEREAS,
Dealer Manager, a FINRA registered broker-dealer, has agreed to serve as the dealer
manager for the Offering and will offer the Shares through other registered broker-dealers that are
members of FINRA (the “Dealers”);

     WHEREAS, it is anticipated that investors will subscribe for the Shares and will provide the
Dealer Manager with subscription payments for such Shares (the “Subscription Payments”),
which subscriptions will be contingent upon (i) their respective acceptances by the Company and
(ii) the Company’s acceptance of subscriptions aggregating $2,000,000 of Shares (the “Minimum
Amount”) deposited into escrow;

     WHEREAS, the Company and the Dealer Manager desire to deposit funds contributed by the
Subscribers (as defined below) with the Escrow Agent, to be held for the benefit of the Subscribers
and the Company until such time as subscriptions for the Minimum Amount has been deposited into
escrow or otherwise in accordance with the terms of this Agreement;

     WHEREAS, the Escrow Agent has agreed to receive and hold in escrow all Subscription Payments
until the earlier of (i) such time as subscriptions for the Minimum Amount have been received and
accepted by the Company or (ii) the close of business on the date exactly one year after the
original effective date of the Prospectus (the Company shall provide notice of such date to Escrow
Agent) (the “Minimum Subscription Termination Date”), and to hold and distribute such
Subscription Payments in accordance with the terms and conditions herein set forth; and

     WHEREAS, the Escrow Agent is willing to accept appointment as the escrow agent for only the
expressed duties, terms and conditions outlined herein.

     NOW, THEREFORE, in consideration of the premises and agreements set forth herein, the parties
hereto agree as follows:

     1. Appointment of Escrow Agent. The Company and the Dealer Manager hereby appoint the
Escrow Agent to serve as escrow agent, and the Escrow Agent hereby accepts such appointment, each
in accordance with the terms of this Agreement. The Company and the

 

 

Dealer Manager hereby acknowledge that the status of the Escrow Agent is that of agent only
for the limited purposes set forth herein, and hereby agree that they will not represent that the
Escrow Agent has investigated the desirability or advisability of investment in the Shares or has
approved, endorsed or passed upon the merits of the investment therein. The Company and the Dealer
Manager further agree that the name of the Escrow Agent shall not be used in any manner in
connection with the offer or sale of the Shares other than to state that the Escrow Agent has
agreed to serve as escrow agent for the limited purposes set forth herein.

     2. Proceeds. Investors subscribing to purchase Shares (the “Subscriber”) will
be instructed by the Dealer Manager or the Dealers to remit the purchase price in the form of
checks, drafts or money orders (the “Payment Instruments”) payable to the order of, or
funds wired in favor of, “Wells Fargo Bank — REITPlus, Inc. Escrow” (the “Escrow
Account”), or, after the Company meets the Minimum Amount, payable to the order of, or funds
wired in favor of “REITPlus, Inc.” Within three (3) business days of receipt of the Payment
Instruments, the Dealer Manager or the Dealers shall remit to the Escrow Agent the Payment
Instruments. Such Payment Instruments shall be retained in the Escrow Account by the Escrow Agent
and invested as set forth in Section 7 and shall be deposited within one (1) business day of
receipt.

     In the event that any Payment Instruments deposited in the Escrow Account prove uncollectible
after the funds represented thereby have been released by the Escrow Agent to the Company, then the
Dealer Manager or Company shall promptly reimburse the Escrow Agent for any and all costs incurred
for such, upon request, and the Escrow Agent shall deliver the uncollectible Payment Instrument to
the Dealer Manager or the Company. Notwithstanding the foregoing, if any Subscriber exercises any
right provided by law to rescind his or her subscription, the Escrow Agent shall, upon notice from
the Company or Dealer Manager, return to such Subscriber all subscription payments pertaining to
such subscription, together with any earnings thereon during the period that such payments were
held by the Escrow Agent under this Agreement.

     3. Subscriber Identity. Within three (3) business days after receipt of the Payment
Instruments, the Dealer Manager shall furnish to the Escrow Agent each accepted Subscriber’s name,
address, social security number or tax identification number, number of Shares purchased and
purchase price remitted. All proceeds so deposited shall be considered the property of the
Subscribers and shall be held for the benefit of such Subscribers and shall not be: (i) commingled
with the monies or become an asset of the Company, or (ii) subject to any liens or charges by the
Company or the Escrow Agent, or judgments or creditors’ claims against the Company, until released
to the Company as hereinafter provided. The Escrow Agent will not use the information provided to
it by the Company for any purpose other than to fulfill its obligations as the Escrow Agent. The
Escrow Agent agrees to treat all Subscriber information as confidential.

     4. Disbursement of Proceeds. On a weekly basis, and at the end of the third business
day following the Minimum Subscription Termination Date (and more frequently, if requested by the
Company), the Escrow Agent shall notify the Company of the amount of Payment Instruments received
since the last report (the “Collected Funds”). If the Collected Funds are in an amount
equal to or greater than the Minimum Amount at any time prior to the Minimum Subscription
Termination Date, and the Company has delivered a written notice (the

-2-

 

“Notice”) stating that the Company has received Collected Funds for the Minimum Amount
of Shares, then the Escrow Agent shall pay out the Collected Funds and all earnings thereon to the
Company when and as directed by the Notice. Following such disbursement, the Escrow Account shall
close and thereafter the Escrow Agent shall forward directly to the Company, upon receipt, any
subscription documents and Payment Instruments received from Subscribers.

     If the Minimum Amount has not been attained prior to the Minimum Subscription Termination
Date, the Escrow Agent shall, within a reasonable time following the Minimum Subscription
Termination Date, but in no event more than ten (10) days after the Minimum Subscription
Termination Date, refund to each of the Subscribers all sums paid by the Subscribers, with a
pro-rata portion of any interest earned thereon.

     In the event that on the Minimum Subscription Termination Date, the Escrow Agent is not in
receipt of evidence of subscriptions accepted on or before such date, and Subscription Payments
dated not later than that date (or actual wired funds) at least equal to the Minimum Amount, the
Escrow Agent shall promptly notify the Company and the Dealer Manager, and the Escrow Agent shall
promptly return all funds received in full directly to the investors, together with their pro rata
share of any interest earned thereon, pursuant to instructions made by the Company or the Dealer
Manager, upon the which the Escrow Agent may conclusively rely.

     5. Duty and Liability of the Escrow Agent. The sole duty of the Escrow Agent, other
than as herein specified, shall be to receive the Subscribers’ Payment Instruments and hold them
subject to release, in accordance herewith, and the Escrow Agent shall be under no duty to
determine whether the Company or Dealer Manager is complying with requirements of this Agreement or
the Prospectus in tendering to the Escrow Agent said proceeds of the sale of the Shares. The
Escrow Agent may conclusively rely upon and shall be protected in acting upon any statement,
certificate, notice, request, consent, order or other document reasonably believed by it to be
genuine and to have been signed or presented by the proper party or parties. The Escrow Agent
shall have no duty or liability to verify any such statement, certificate, notice, request,
consent, order or other document, and its sole responsibility shall be to act only as expressly set
forth in this Agreement. The Escrow Agent shall be under no obligation to institute or defend any
action, suit or proceeding in connection with this Agreement unless first indemnified to its
satisfaction. The Escrow Agent may consult and hire counsel in respect of any question arising
under this Agreement, and the Escrow Agent shall not be liable for any action taken or omitted in
good faith upon advice of such counsel.

     The Escrow Agent is acting solely as escrow agent hereunder and owes no duties, covenants or
obligations, fiduciary or otherwise, to any other person by reason of this Agreement, except as
otherwise stated herein, and no implied duties, covenants or obligations, fiduciary or otherwise,
shall be read into this Agreement against the Escrow Agent. In no event shall the Escrow Agent be
liable, directly or indirectly, for any special, indirect or consequential losses or damages of any
kind whatsoever (including without limitation lost profits), even if the Escrow Agent has been
advised of the possibility of such losses or damages and regardless of the

-3-

 

form of action. The parties agree that the Escrow Agent has no role in the preparation of the
Offering documents, has not reviewed any such documents and makes no representations or warranties
with respect to the information contained therein or omitted therefrom. The Escrow Agent agrees
that it may be named in the Prospectus and offering documents, to the extent necessary to describe
this Agreement and the duties of the Escrow Agent herein. The Escrow Agent shall have no
obligation, duty or liability with respect to compliance with any federal or state securities,
disclosure or tax laws concerning the offering documents or the issuance, offering or sale of the
Shares. The Escrow Agent shall have no duty or obligation to monitor the application and use of
the Subscriber funds once transferred to the Company, that being the sole obligation and
responsibility of the Company.

     6. Escrow Agent Fee. The Escrow Agent shall be entitled to compensation for its
services, as stated in the fee schedule attached hereto as Exhibit A, which compensation
shall be paid by the Company. Subject to the provisions of Section 9, the fee agreed upon for the
services rendered hereunder in Exhibit A is intended as full compensation for the Escrow
Agent’s services as contemplated by this Agreement. Notwithstanding anything contained herein to
the contrary, in no event shall any fee, reimbursement for costs and expenses, indemnification for
damages incurred by the Escrow Agent or monies whatsoever be paid out of or chargeable to the
income of assets of the Escrow Account.

     7. Investment of Subscription Payments. The Escrow Agent shall invest all Collected
Funds in the Wells Fargo Advantage Funds, 100% Treasury Money Market Fund (the
“Fund”). Any interest received by the Escrow Agent with respect to the Funds, including
reinvested interest shall become part of the proceeds of the Escrow Account (the “Escrow
Income”), and shall be disbursed to the Company if Collected Funds, including interest
earnings, total the Minimum Amount. For tax reporting purposes, all interest or other taxable
income earned on the Investor Funds in any tax year shall be taxable to the person or entity
receiving the interest or other taxable income.

     The Company shall, within thirty (30) days after the date hereof, provide the Escrow Agent
with certified tax identification numbers by furnishing appropriate IRS forms W-9 or W-8 and other
forms and documents that the Escrow Agent may reasonably request, The parties hereto understand
that if such tax reporting documentation is not so certified to the Escrow Agent, the Escrow Agent
may be required by the Internal Revenue Code of 1986, as amended, to withhold a portion of any
interest or other income earned on the Investor Funds pursuant to this Agreement.

     To the extent that the Escrow Agent becomes liable for the payment of any taxes in respect of
income derived from the investment of funds held or payments made hereunder, the Escrow Agent shall
satisfy such liability to the extent possible from the Investor Funds. The Company agrees to
indemnify and hold the Escrow Agent harmless from and against any taxes, additions for late
payment, interest, penalties and other expenses that may be assessed against the Escrow Agent on or
with respect to any payment or other activities under this Agreement unless any such tax, addition
for late payment, interest, penalties and other expenses shall arise out of or be caused by the
gross negligence or willful misconduct of the Escrow Agent.

-4-

 

     8. Notices. All notices, requests, demands, and other communications under this
Agreement shall be in writing and shall be deemed to have been duly given (a) on the date of
service if served personally on the party to whom notice is to be given, (b) on the day of
transmission if sent by facsimile transmission to the facsimile number given below, and written
confirmation of receipt is obtained promptly after completion of transmission, (c) on the day after
delivery to Federal Express or similar overnight courier or the Express Mail service maintained by
the United States Postal Service, or (d) on the fifth day after mailing, if mailed to the party to
whom notice is to be given, by first class mail, registered or certified, postage prepaid, and
properly addressed, return receipt requested, to the party as follows:

If to Company:

REITPlus, Inc.

8 Greenway Plaza, Suite 1000

Houston, Texas 77046

Attention: Chief Executive Officer

Fax: 713-850-0498

If to the Dealer Manager:

AmREIT Securities Company

8 Greenway Plaza, Suite 1000

Houston, Texas 77046

Attention: President

Fax: 713-850-0498

If to the Escrow Agent:

Wells Fargo Bank, N.A.

1021 Main Street, 24th Floor

MAC T5017-241

Houston, Texas 77002-6502

Attention: Deirdre Ward, Corporate Trust & Escrow Services

Fax: 713-289-3488

Wires to the Escrow Agent should be directed to the following:

Wells Fargo Bank, National Association

ABA #121000248

A/C # 22276100

For Further Credit to: REITPlus, Inc. Subscription Escrow

Re: REITPlus, Inc.

Attention: Deirdre Ward, 713-289-3463

Any party may change its address for purposes of this paragraph by giving the other party written
notice of the new address in the manner set forth above.

-5-

 

     9. Indemnification of the Escrow Agent. The Company and the Dealer Manager hereby
jointly and severally indemnify and hold the Escrow Agent (and its officers, directors, employees
and agents) harmless from and against any and all loss, claim, liability, cost, damage and expense,
including, without limitation, reasonable counsel fees and expenses, which the Escrow Agent may
suffer or incur by reason of any action, claim or proceeding brought against the Escrow Agent
arising out of or relating in any way to this Agreement or any transaction to which this Agreement
relates unless such action, claim or proceeding is the result of the willful misconduct or gross
negligence of the Escrow Agent. The provisions of this section shall survive the termination of
this Agreement and the resignation or removal of the Escrow Agent.

     10. Successors and Assigns.

          (a) Except as otherwise provided in this Agreement, no party hereto shall assign this
Agreement or any rights or obligations hereunder without the prior written consent of the other
party hereto and any such attempted assignment without such prior written consent shall be void and
of no force and effect. This Agreement shall inure to the benefit of and shall be binding upon the
heirs, executors, administrators, successors and permitted assigns of the parties hereto.

          (b) Notwithstanding the above, any corporation or association into which the Escrow Agent may
be converted or merged, or with which it may be consolidated, or to which it may sell or transfer
all or substantially all of its corporate trust business and assets as a whole or substantially as
a whole, or any corporation or association resulting from any such conversion, sale, merger,
consolidation or transfer to which the Escrow Agent is a party, shall be and become the successor
Escrow Agent under this Agreement and shall have and succeed to the rights, powers, duties,
immunities and privileges as its predecessor, without the execution or filing of any instrument or
paper or the performance any further act.

     11. Term. This Agreement shall terminate within thirty (30) days receipt of written
notice of termination by the Company and Dealer Manager to the Escrow Agent. In the event of the
release of all Subscriber funds and all accrued interest in accordance with Section 4 of this
Agreement, this Agreement shall terminate and the Escrow Agent shall be relieved of all
responsibilities in connection with the Escrow Account, except claims which are occasioned by its
gross negligence or willful misconduct.

     12. Governing Law; Jurisdiction. This Agreement shall be construed, performed, and
enforced in accordance with, and governed by, the internal laws of the State of Delaware, without
giving effect to the principles of conflicts of laws thereof. Each party hereby consents to the
personal jurisdiction and venue of any court of competent jurisdiction in the State of Delaware.

     13. Severability. In the event that any part of this Agreement is declared by any
court or other judicial or administrative body to be null, void, or unenforceable, said provision
shall survive to the extent it is not so declared, and all of the other provisions of this
Agreement shall remain in full force and effect.

-6-

 

     14. Amendments; Waivers. This Agreement may be amended or modified, and any of the
terms, covenants, representations, warranties, or conditions hereof may be waived, only by a
written instrument executed by the parties hereto or, in the case of a waiver, by the party waiving
compliance. Any waiver by any party of any condition, or of the breach of any provision, term,
covenant, representation, or warranty contained in this Agreement, in any one or more instances,
shall not be deemed to be nor construed as further or continuing waiver of any such condition, or
of the breach of any other provision, term, covenant, representation, or warranty of this
Agreement.

     15. Entire Agreement; Counterparts. This Agreement contains the entire understanding
among the parties hereto with respect to the escrow contemplated hereby and supersedes and replaces
all prior and contemporaneous agreements and understandings, oral or written, with regard to such
escrow. This Agreement, and any amendments hereto, may be executed by the parties hereto in one or
more counterparts, each of which shall be deemed an original.

     16. Section Headings. The section headings in this Agreement are for reference
purposes only and shall not affect the meaning or interpretation of this Agreement.

     17. Disputes. In the event of a disagreement among any of the parties to this
Agreement, or among them or any other person resulting in adverse claims and demands being made in
connection with or from any property in the Escrow Account, the Escrow Agent shall be entitled to
refuse to comply with any such claims or demands as long as such disagreement may continue, and in
so refusing, shall make no delivery or other disposition of any property then held by it in the
Escrow Account under this Agreement, and in so doing, the Escrow Agent shall be entitled to
continue to refrain from acting until (i) the right of adverse claimants shall have been finally
settled by binding arbitration or finally adjudicated in a court assuming and having jurisdiction
of the property involved herein or affected hereby or (ii) all differences shall have been adjusted
by agreement and the Escrow Agent shall have been notified in wiritng of such agreement signed by
the parties hereto.

     In the event of such dispute, the Escrow Agent shall be entitled, in its discretion and
judgment, to tender into the registry or custody of any court of competent jurisdiction all money
or property in its hands under this Agreement, together with such legal pleadings as the Escrow
Agent deem appropriate, and thereupon be discharged from all further duties and liabilities under
this Agreement. In the event of any uncertainty as to its duties hereunder, the Escrow Agent may
refuse to act under the provisions of this Agreement pending order of a court of competent
jurisdiction and the Escrow Agent shall have no liability to the Company, the Dealer Manager or to
any other person as a result of such action. Any such legal action may be brought in such court as
the Escrow Agent shall determine to have jurisdiction thereof. The filing of any such legal
proceedings shall not deprive the Escrow Agent of its compensation earned prior to such filing.

     18. Limited Purpose. The Company and Dealer Manager hereby acknowledge that the Escrow
Agent is serving as the escrow agent only for the limited purposes herein set forth, and hereby
agree that they will not represent or imply that the Escrow Agent, by serving as the Escrow Agent
hereunder or otherwise, have investigated the desirability or advisability of

-7-

 

investment in the Company or have approved, endorsed or passed upon the merits of the Shares, nor
shall they use its name in any manner whatsoever in connection with the offer or sale of the Shares
other than by acknowledgment that the Escrow Agent has agreed to serve as the Escrow Agent for the
limited purposes set forth herein.

     19. Resignation. The Escrow Agent may resign upon 30 days advance written notice to
the Company and the Dealer Manager. Such resignation shall become effective on the date specified
in such notice, which shall be not earlier than 30 days after such written notice has been given.
In the event of any such resignation, a successor escrow agent, which shall be a bank or trust
company organized under the laws of the United States of America, shall be appointed by the mutual
agreement of the Company and the Dealer Manager. Any such successor escrow agent shall deliver to
the Company and the Dealer Manager a written instrument accepting such appointment, and thereupon
shall succeed to all the rights and duties of the Escrow Agent hereunder and shall be entitled to
receive the Escrow Account from the Escrow Agent. The Escrow Agent shall promptly pay the
Subscription Payments in the Escrow Account, including interest thereon, to the successor escrow
agent. If a successor Escrow Agent is not appointed by the Company or the Dealer Manager within
the 30-day period following such notice, the Escrow Agent may petition any court of competent
jurisdiction to name a successor Escrow Agent. All costs, expenses and reasonable attorneys fees
for which the Escrow Agent incurs in connection with such proceeding shall be paid by the Company.

     20. Removal. The Escrow Agent may be jointly removed by the Company and the Dealer
Manager at any time, by written notice executed by both of them (which may be executed in
counterparts) provided to the Escrow Agent, which instrument shall become effective on the date
specified in such written notice. The removal of the Escrow Agent shall not deprive the Escrow
Agent of its compensation earned prior to such removal. In the event of any such removal, a
successor escrow agent, which shall be a bank or trust company organized under the laws of the
United States of America, shall be appointed by the mutual agreement of the Company and the Dealer
Manager. Any such successor escrow agent shall deliver to the Company and the Dealer Manager a
written instrument accepting such appointment, and thereupon shall succeed to all the rights and
duties of the Escrow Agent hereunder and shall be entitled to receive the Escrow Account from the
Escrow Agent. The Escrow Agent shall promptly pay the Subscription Payments in the Escrow Account,
including interest thereon, to the successor escrow agent. If a successor escrow agent is not
appointed by the Company or the Dealer Manager within the 30-day period following such notice, the
Escrow Agent may petition any court of competent jurisdiction to name a successor escrow agent.
All costs, expenses and reasonable attorneys fees for which the Escrow Agent incurs in connection
with such proceeding shall be paid by the Company.

     21. Maintenance of Records. The Escrow Agent shall maintain accurate records of all
transactions hereunder. Promptly after the termination of this Agreement, and as may from time to
time be reasonably requested by the Company before such termination, the Escrow Agent shall provide
the Company with a copy of such records, certified by the Escrow Agent to be a complete and
accurate account of all transactions hereunder. The authorized representatives of the Company and
the Dealer Manager shall also have access to the Escrow Agent’s books and

-8-

 

records to the extent relating to its duties hereunder, during normal business hours upon
reasonable notice to the Escrow Agent, and at the requesting party’s expense.

[Signatures Appear on Following Page]

-9-

 

     IN WITNESS WHEREOF, the parties hereto have caused this Escrow Agreement to be executed the
day and year first set forth above.

	 	 	 	 	 	 	 
	 	 	REITPLUS, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 	 	 
	 	 	Name: Chad C. Braun	 	 
	 	 	Title: Executive Vice President and Chief Financial Officer	 	 

	 	 	 	 	 	 	 
	 	 	WELLS FARGO BANK,
NATIONAL ASSOCIATION, as Escrow Agent	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	Name:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	Title:	 	 	 	 
	 

	 	 	 	 

	 	 

-10-

 

Exhibit A

REITPlus, Inc.

and

Wells Fargo Bank, N.A.

Escrow Agent Services — Fee Schedule

			
	Acceptance Fee:
	 	Waived

Initial Fees as they relate to Wells Fargo Bank acting in the capacity of Escrow Agent — includes
creation and examination of the Escrow Agreement; acceptance of the Escrow appointment; setting up
of Escrow Account(s) and accounting records; and coordination of receipt of funds for deposit to
the Escrow Account. Acceptance Fee payable at time of Escrow Agreement execution.

	 	 	 	 	 	 	 
	Escrow Agent Administration Fee:

	 	For up to 40 Investor Deposits:
	 	$	2,500.00	 

     For ordinary administration services by Escrow Agent — includes daily routine account management;
investment transactions; cash transaction processing (including wires and check processing);
disbursement of the funds in accordance with the agreement; and mailing of trust account statements
to all applicable parties. Tax reporting is included for up to One (1) entity. Should additional
reportings be necessary, a $25 per reporting charge will be assessed. Float credit received by the
bank for receiving funds that remain uninvested are deemed part of the Paying Agent/Escrow Agent’s
compensation. Fees are due and payable upon execution of documents. Fee will not be prorated in
case of early termination.

Transaction Charges:

	 	 	 	 	 	 	 
	Subscription Disbursements to investors by check or wire
	 	 	 	 	 	 
	(Assuming Minimum Amount is not met)
	 	 	 	$25peritem
	Subscription receipts in excess of 40
	 	 	 	$20peritem
	International Wire disbursements
	 	 	 	$85perwire
	NSF checks, stop payments, return checks
	 	 	 	$35percheck
	Tax Reporting (if necessary)
	 	 	 	$25perinvestor

Out of Pocket Expenses:

     We only charge for out-of-pocket expenses in response to specific tasks assigned by the client.
Therefore, we cannot anticipate what specific out-of-pocket items will be needed or what
corresponding expenses will be incurred. Possible expenses would be, but are not limited to,
express mail and messenger charges, travel expenses to attend closing or other meetings. There
are no charges for indirect out-of- pocket expenses.

Wells Fargo’s fees are based on the following assumptions:

	•	 	Number of escrow funds/accounts to be established: One (1)
	 
	•	 	Number of Deposits to Escrow Account: See above.
	 
	•	 	Number of Withdrawals from Escrow Fund: Various over term of escrow.
	 
	•	 	Term of Escrow: Less than 1 year
	 
	•	 	THIS FEE SCHEDULE ASSUMES THAT BALANCES IN THE ESCROW ACCOUNT WILL BE INVESTED IN MONEY
MARKET MUTUAL FUNDS
	 
	•	 	ALL FUNDS WILL BE RECEIVED FROM OR DISTRIBUTED TO A DOMESTIC ENTITY
	 
	•	 	IF THE ACCOUNT(S) DOES NOT OPEN WITHIN THREE (3) MONTHS OF THE DATE SHOWN BELOW, THIS
SCHEDULE WILL BE DEEMED TO BE NULL AND VOID

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}]]